



Azerbaijan Medical Journal
Verify Mail
To: irham.taufiqurrahman@ulm.ac.id

Inbox - ULM 2 May 2023 13.19

Azerbaijan Medical Journal

Sub: Verify Email Address

Dear **Irham**,

Please click the button below to verify your email address

[Verify Email Address](#)

If you're having trouble clicking the "Verify Email Address" button, copy and paste the URL below into your web browser:

<https://www.azerbaijanmedicaljournal.com/author/verification-done/2/Dr/Irham/Taufiqurrahman/irham.taufiqurrahman@ulm.ac.id/Lambung%20Mangkurat%20University/department/Indonesia/Irham@999/default.png>

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to support@azerbaijanmedicaljournal.com and related documents mail to admin@azerbaijanmedicaljournal.com

Azerbaijan Medical Journal, Azerbaijan © 2021 All rights reserved.
Don't like these emails? [Unsubscribe](#).

Found in Gmail Inbox



Azerbaijan Medical Journal
To: irham.taufiqurrahman@ulm.ac.id >

06/06/23

Thank your for your submission

Azerbaijan Medical Journal

Date: 05 Jun 2023
Sub: Submission Succeeded
Paper ID: **AMJ-05-06-2023-11524**

Dear **Dr Irham**,

Thank you for your submission into "**Azerbaijan Medical Journal**". Please use this paper ID: "**AMJ-05-06-2023-11524**" for your further inquiry for the publication. The paper will now go through peer review process and you will be notified within 7 working days about your submitted paper.

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to
support@azerbaijanmedicaljournal.com and related documents mail to
admin@azerbaijanmedicaljournal.com

Azerbaijan Medical Journal, Azerbaijan © 2021 All rights reserved.
Don't like these emails? [Unsubscribe](#).

DASHBOARD

↓ SUBMISSION

- Submissions
- + New Submit

[Submission Guideline](#)

[Home Page](#)

Irham

Show 10 entries

Search:

#Sl#	Paper ID	OTP Code	Paper Title	Date	Status	Payment	Action
1	AMJ-05-06-2023-11524	Not Available	An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (Bouea macrophylla Griffith) Against Angiotensin-2	05 Jun 2023	Pending	Wait for Approved	



Irham Taufiqurrahman

Correspondence

To: support@azerbaijanmedicaljournal.com, admin@azerbaijanmedicaljournal.com

Sent - ULM 9 June 2023 16:57

Date: 09 Jun 2023

Title: An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (Bouea macrophylla Griffith) Against Angiotensin-2

Sub: Manuscript Submission

Paper ID: AMJ-05-06-2023-11524

Dear, Admin Board Azerbaijan Medical Journal

Thank you for responding to the submission of our manuscript to the "Azerbaijan Medical Journal". We have followed all the rules regarding the writing of manuscripts from this journal. We ask for directions and responses regarding writing from abstracts to bibliography.

Thank you,
Dr Irham
Corresponding author



Azerbaijan Medical Journal

To: irham.taufiqurrahman@ulm.ac.id >

12/06/23

Your paper has been revised

Azerbaijan Medical Journal

Date: 12 June 2023

Sub: Paper Revised


Paper ID: AMJ-05-06-2023-11524

Dear Dr. Irham,

Thank you for Submitting your manuscript into Azerbaijan Medical Journal. We are Pleased and honored to inform you that your paper "**An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (Bouea macrophylla Griffith) Against Angiotensin-2**" has been revised by our Editorial board.

If you have any query, Please do not hesitate to mail us. Please fill your paper ID in to the subject of the mail for further inquiry. We eagerly await your response.

Thank you,
Admin Board
Azerbaijan Medical Journal



N.B: For Any Queries, Please mail to

support@azerbaijanmedicaljournal.com and related documents mail to

admin@azerbaijanmedicaljournal.com

Azerbaijan Medical Journal, Azerbaijan © 2021 All rights reserved.
Don't like these emails? [Unsubscribe](#).

An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (*Bouea macrophylla* Griffith) Against Angiopoietin-2

Irham Taufiqurrahman^a, Isyana Erlita^b, Mira Hadistina^c, Juliyatin Putri Utami⁴, Andi Zulkifli^e, Veni Hadju^e, Eko Suhartono^f, Muhammad Irpan Hendrawan^g

^aDepartement of Oral and Maxillofacial Surgery, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia

^bDepartment of Conservative Dentistry, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia

^cFaculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia

⁴Department of Biomedicine Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia

^eFaculty of Public Health, Hasanuddin University, Makassar - Indonesia

^fDepartment of Medical Chemistry/Biochemistry, Faculty of Medicine, Lambung Mangkurat University, Indonesia

^gFaculty of Dentistry, Hasanuddin University, Makassar, Indonesia

*Corresponding author : irham.taufiqurrahman@ulm.ac.id

Abstract—Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti and colleagues, the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59%. Purpose: To determine the active compound binding of *Bouea macrophylla* G. (*ramania*) as an anti-inflammatory by inhibiting the protein angiopoietin-2 (Ang-2) in silico. Method: Experimental design through in silico method. Result: Methyl ricinoleate compound has RMSD (Root Mean Square Deviation) value of 0 and negative binding affinity value, hydrogen bonding, and the same residue as the comparison ligand, atorvastatin. All active compounds of *Bouea macrophylla* G. has passed the drug likeness test with Lipinski's Rule parameters. Based on the results of the ADMET test, it is known that the absorption of methyl ricinoleate compounds can be absorbed well, the absorption of Caco-2 cells is the highest compared to the 9 active compounds of *Bouea macrophylla* G. and atorvastatin, the volume of distribution and total clearance is better than atorvastatin, does not inhibit CYP50, is not mutagenic, carcinogenic, and not hepatotoxic, has lower Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) values compared to atorvastatin. Conclusion: Methyl ricinoleate can potentially be an anti-inflammatory drug through the inhibition of Ang-2.

Keywords — Anti-inflammatory, Ramania.

Commented [AMJ1]: use numbers for correspondence name markers

Commented [AMJ2]: use at least 3 keywords

1. Introduction

Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact [1]. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti et al (2018), the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59% [2], [3]. TDI trauma that occurs often involves many tissues and takes a lot of time to treat, so treatment is relatively expensive and difficult. Some drugs such as antibiotics are also used in addition to surgery [1], [4].

The use of drugs in wound healing is available with various kinds and types, including the use of herbal medicines. Herbal medicine is an alternative in medicine because the price is cheap, the ingredients are relatively easy to obtain and do not cause side effects. *Bouea macrophylla* G. can be selected as a plant that can play a role in accelerating wound healing. It is known that the leaves of *Bouea macrophylla* G. contain compounds of caryophyllene, humulene; hexadecanoic acid, ethyl ester (palmitic acid); phytol; squalene; vitamin E; retinol, acetate; and γ -himachalene which has potential as an anti-inflammatory [5-7].

Treatment of wound healing in soft tissue aims to clean the wound area from foreign objects, dead cells and bacteria so as to support the healing process. As the body's response to wound healing, there is an inflammatory process that involves: a number of endothelial growth factors. One of the proteins derived from endothelial growth factor is the protein angiopoietin-2 (Ang-2).

The comparison ligand used was an Ang-2 inhibitor, namely atorvastatin. The comparison protein used in protein-to-protein docking is Tyrosine Kinase-2 (Tie2). This study predicts the therapeutic target for Ang-2 by using 10 active compounds *Bouea macrophylla* G.

Commented [AMJ3]: describe Ang-2 along with its function and mechanism

2. Materials & method

2.1 Ligand and Protein Preparation

Receptors namely Ang-2 and Tie2 were prepared using Biovia Discovery Studio application to remove water molecules and residues. The ligands, namely the active compound *Bouea macrophylla* G. and atorvastatin, were prepared using the Open Babel program from PyRx version 0.8 to minimize energy, optimize, and convert the format to .pdb.

2.2 Validation

The validation process was carried out by re-docking the Ang-2 protein with its natural ligand (calcium ion) (CID:336285734). The parameter used is the RMSD (Root Mean Square Deviation) value. The validation results obtained are 0. RMSD is a value associated with the deviation of the binding position. The docking method is said to be valid if the RMSD value is ≤ 2 , so the docking method can be used for the docking test of active compounds.

2.3 Protein-Ligand Docking and Visualization

Molecular docking simulation using AutoDock Vina program which is integrated with PyRx. The analysis and visual prediction of the protein-ligand complex virtual from the docking stage were analyzed and visualized using the Biovia Discovery Studio version 21 application. The interaction side was analyzed based on the residual ligand interaction and structural conformation. Ang-2 was also docked with atorvastatin to compare the binding affinity values of 10 *Bouea macrophylla* G compounds.

2.4 Prediction of drug-likeness, pharmacokinetics, and safety

Lipinski's Rule of 5 used to predict drug similarity to the active compound, which was evaluated by the pkCSM website (<http://biosig.unimelb.edu.au/pkcsm/prediction>) and PubChem (<https://pubchem.ncbi.nlm.nih.gov/>).

Commented [AMJ4]: what version of the app are you using? enter into paragraphs

Commented [AMJ5]: Please describe the PyRx version you are using

3. Results

In **Table 1**, it can be seen that the highest molecular weight is owned by atorvastatin with a weight of 558.65 g/mol and the lowest weight is a compound of humulene and a compound of γ -himachalene with a weight of 204.357 g/mol. The best logP values were owned by *carophyllene* compounds and γ -himachalene compounds with a logP of 4.7252. While the largest is squalene compound with logP 10,605. All of the active compounds have good hydrogen acceptors, Bouea macrophylla G. Meanwhile, all of the tested active compounds of Bouea macrophylla G. have < 5 . The widest topological polar surface area (TPSA) (Table 1) is owned by atorvastatin compounds with an area of 112. Based on Table 1, it was found that all active compounds of Bouea macrophylla G. leaf extract passed the Lipinski's rules test.

All the active compounds of Bouea macrophylla G. tested (**Table 2**) were well absorbed in the human intestine. The highest absorption of Caco-2 cells was methyl ricinoleate with a value of 1.57 log cm/s. The highest VDss value was found in vitamin E compounds with a VDss value of 0.873 log L/kg.

The 10 active compounds tested Bouea macrophylla G. (**Table 2**) did not act as CYP2D6 inhibitors, so their pharmacokinetic properties were enzymatic. The highest total clearance value was owned by *squalene* compound with a value of 1.791 log mL/minute/kg.

All tested Bouea macrophylla G. compounds were neither mutagenic nor carcinogenic, nor was atorvastatin. In the hepatotoxicity test (Table 2.), it was found that all Bouea macrophylla G. compounds were not hepatotoxic, except for the retinol compound, acetate, which resulted in hepatotoxicity as well as *atorvastatin*. The highest LD50 is owned by atorvastatin with a value of 2.877 mol/kg. The highest LOAEL was owned by *atorvastatin*.

Table 3. The binding affinity value obtained varies from -3.3 kcal/mol to -6.5 kcal/mol. The lowest bond value was owned by the Ang-2_atorvastatin bond of -6.5 kcal/mol. While the highest is the Ang-2_palmitic acid bond. Ang-2_Bond Methyl ricinoleate has 2 hydrogen bonds. In addition, the Ang-2_methyl ricinoleate bond has the same residue as the Ang-2_atorvastatin bond residue, namely the GLU35 residue. The result of Ang-2_pristanal docking also has 2 hydrogen bond interactions. Meanwhile, Ang-2_retinol, acetate; Ang-2_phytol; and Ang-2_palmitic acid has a hydrogen bond type interaction, while the Ang-2_ γ -himachlene bond; Ang-2_vitamin E bond; bond Ang-2_carophyllene; bond Ang-2_humulene; Ang-2_squalene bonds have no hydrogen-type bond interactions.

The most negative binding affinity value from the results of docking to protein (Table 4.) is the result of docking tyrosine kinase-2 (Tie2) with Ang-2_carophyllene bonds with a value of -8.1 kcal/mol, higher than the binding affinity value of Tie2_Ang-2_atorvastatin with a value of -7.5 kcal/mol. While the highest is Tie2_Ang-2_palmitic acid with a value of -4 kcal/mol.

The amino residues on the interaction bonds found in the protein-to-protein docking results (**Table 4**) were almost all similar to the amino acid residues from the docking of Ang-2 with the active compounds Bouea macrophylla G. and *atorvastatin*, except for the docking results of Tie2_Ang-2_pristanal at residues MET857 and PHE869, Tie2_Ang-2_methyl ricinoleate. Tie2_Ang-2_methyl ricinoleate has the same residues with a total of 12 residues that are the same as Tie2_Ang-2_atorvastatin, namely at residues LYS855, ARG856, VAL829, LEU839.

Hydrogen bond interactions from protein to protein docking results (**Table 4**) from Tie2_Ang-2_10 active compound Bouea macrophylla G. and Tie2_Ang-2_atorvastatin bonds were mostly found in Tie2_Ang-2_atorvastatin bonds with 5 hydrogen bonds at residues LYS855, ARG856, LYS858 and bonds Tie2_Ang-2_methyl ricinoleate on residues LYS855, ARG856 (3.25349 and 3, 37493), GLN837, and CO. Meanwhile, the Tie2_Ang-2_carophyllene bond, the Tie2_Ang-2_pristanal bond, the Tie2_Ang-2_humulene bond, and the Tie2_Ang-2_ γ -himachlane bond did not have hydrogen bonds.

Commented [AMJ6]: describe the LOAEL value

Table 1. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand Atorvastatin Correlation with Lipinski's Rule.

Compound	Molecular Weight (g/mol)	LogP	Hydrogen Acceptors (n)	Hydrogen Donor (n)	TPSA (Topological Polar Surface Area)	Lipinski's Law Deviations	Pass/No
<i>Carophyllene</i>	204.537	4.7252	0	0	0	0	Graduated
<i>2-Methyl-cis-7, 8-epoxynonadecane (Pristanal)</i>	296.539	6.8911	1	0	12.5	1	Graduated
<i>Humulene</i>	204,357	5.0354	0	0	0	1	Graduated
<i>Hexadecanoic acid, ethyl ester (Palmitic acid)</i>	284,484	6.1884	1	1	37.3	1	Graduated
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans- (Methyl ricinoleate)</i>	312,494	5.5673	2	1	46.5	1	Graduated
<i>Phytol</i>	296.539	6.3641	1	1	20.2	1	Graduated
<i>Retinol, Acetate</i>	328,496	6.0811	2	0	26.3	1	Graduated
Vitamin E	430.717	8.84026	2	1	29.5	1	Graduated
<i>γ-himachalene</i>	204,357	4.7252	0	0	0	0	Graduated
<i>Squalene</i>	410.73	10,605	0	0	0	1	Graduated
<i>Atorvastatin</i>	558.65	6,3136	5	4	112	2	Graduated

Table 2. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand Atorvastatin

Compound	Caco-2 permeability (nm.sec-1)	Human Intestinal Absorption (%)	VDss (log L/kg)	CYP 2D6 Inhibitor	Total Clearance	AMES Toxicity	Hepatotoxicity	Oral Rate Acute Toxicity (LD50) (mol/kg)	Oral Rate Chronic Toxicity (LOAEL) (log mg/kg_bw/day)
<i>Carophyllene</i>	1.434	95.304	0.653	No	1.088	No	No	1,678	1.44
<i>2-Methyl-cis-7, 8-epoxy-nonadecane</i>	1.32	91,567	0.451	No	1,631	No	No	1.382	1.028
<i>Humulene</i>	1.421	94,682	0.505	No	1,282	No	No	1,766	1.336
<i>Hexadecanoic acid, ethyl ester</i>	1.38	92,158	-0.679	No	1,678	No	No	1.46	3.298
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-</i>	1.57	91,956	-0.509	No	1.615	No	No	1.573	2,701
<i>Phytol</i>	1.487	89,892	0.416	No	1,686	No	No	1,646	1.024
<i>Retinol, Acetate</i>	1.188	94.33	0.408	No	1.503	No	Yes	1,673	2.276
Vitamin E	1,215	90,045	0.873	No	0.801	No	No	2,243	2.445
<i>γ-himachalene</i>	1.418	94.556	0.648	No	1.093	No	No	1,681	1.346
<i>Squalene</i>	1.193	89,581	0.282	No	1,791	No	No	1995	0.902
<i>Atorvastatin</i>	0.23	59,861	-1.918	No	0.437	No	Yes	2.877	4.839

Table 3. Results of Docking Ang-2 with Bouea macrophylla G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-5.3	ILE309, LYS310	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxynonadecane</i> (Pristanal)	-4.2	GLY347, GLY345	<i>hydrogen</i>
		LYS310, VAL344, ILE309, PRO349, LYS340	<i>Hydrophobic</i>
<i>Humulene</i>	-4.8	-	-
<i>Hexadecanoic acid, ethyl ester</i> (Palmitic acid)	-3.3	PHE346	<i>hydrogen</i>
		ILE309, VAL344, LYS310	<i>Hydrophobic</i>
*Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-(Methyl ricinoleate)	-4.5	GLU395, *GLU358	<i>hydrogen</i>
		PRO303	<i>Hydrophobic</i>
<i>Phytol</i>	-4	GLU308	<i>hydrogen</i>
		LYS310	<i>Unfavorable</i>
		PRO349, ILE309, VAL344	<i>Hydrophobic</i>
<i>Retinol, Acetate</i>	-5.7	LYS372	<i>hydrogen</i>
		ALA494, VAL370, LEU386	<i>Hydrophobic</i>
Vitamin E	-5.4	PHE469, PRO452, PHE469, PHE469, TYR475, TYR475	<i>Hydrophobic</i>
<i>y-himachalene</i>	-5.8	MET458	<i>Hydrophobic</i>
<i>Squalene</i>	-4.4	ILE309, LYS310, PRO349, VAL344, VAL344	<i>Hydrophobic</i>
<i>Atorvastatin</i>	-6.5	SER393, TYR391	<i>hydrogen</i>
		*GLU358, *GLU358	<i>Halogen</i>
		ASN365, HIS402	<i>Unfavorable</i>

* =The same residue as the comparison ligand




Figure 1.a. 3D Structure of Ang-2 docked

Commented [AMJ7]: Docked with?




Figure 2.a. 3D structure of Ang-2 docked with Atorvastatin, b. 2D structure of Ang-2 docked with Atorvastatin

Table 4. Results of Docking Tie2_Ang-2 with Bouea macrophylla G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-8.1	*VAL829	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxynonadecane (Pristanal)</i>	-4.7	*VAL829, *VAL829, *VAL829, *ARG856, *ARG856, *LYS858 *LYS858, MET857, *LEU839, *LEU839, *ARG856, *VAL829, PHE869	<i>Hydrophobic</i>
<i>Humulene</i>	-7.9	VAL829	<i>Hydrophobic</i>
<i>Hexadecanoic acid, ethyl ester (palmitic acid)</i>	-4	*LYS855, *ARG856 *VAL829, *VAL829, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-(Methyl ricinoleate)</i>	-5.6	*LYS855, *ARG856, GLN837, *ARG856, CO, *VAL829, *VAL829, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Phytol</i>	-5	*ARG856 *VAL829, *VAL829, *LEU839, *LYS858, *LYS858	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Retinol, Acetate</i>	-6.7	THR1016, ASN1018 TYR1012, TYR992, VAL1014, TYR1012	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Vitamin E</i>	-6.8	*LYS855 *VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrogen Bond; Electrostatic</i> <i>Hydrophobic</i>
<i>γ-himachalene</i>	-7.1	*VAL829, *LEU839, *ARG856, *VAL829, *VAL829, *LEU839	<i>Hydrophobic</i>
<i>Squalene</i>	-4.8	LYS1059, LEU1061, ALA1114, LYS1059, TYR1068, TYR1068	<i>Hydrophobic</i>
<i>Atorvastatin</i>	-7.5	*LYS855, *ARG856, *LYS858, *ARG856 *LYS855 *LEU839, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrogen Bond</i> <i>Hydrogen Bond; Electrostatic</i> <i>Hydrophobic</i>




Figure 3.a. Result 3D Structure Docking Protein Tie2_Ang-2 with *Methyl Ricinoleate*, b. 2D Structure of Tie2_Ang-2 Protein Docking Result with *Methyl Ricinoleate*




Figure 4. a. Result 3D Structure of Docking Protein Tie2_Ang-2 with *Atorvastatin*, b. 2D Structure of Tie2_Ang-2 Protein Docking Results with *Atorvastatin*

4. Discussion

Table 1. All active compounds of *Bouea macrophylla* G. can be potential candidates for oral drugs because all active compounds of *Bouea macrophylla* G. leaves passed the Lipinski test. Neidle et al. (2019) stated that good absorption is absorption that meets 3 or more Lipinski's rules. [11], [12].

In the pharmacokinetic test results (Table 2.), all tested active compounds of *Bouea macrophylla* G. were well absorbed in the human intestine, because the percentage absorption of all tested compounds was >89%. Based on Utami et al. (2022), the value of good absorption in the human intestine is 70-100% [13][14].

Caco-2 cells are permeability parameters used to determine drug transport through specialized epithelium derived from human colonic adenocarcinoma which has multiple transport pathways. The parameter categories of Caco-2 cells were >70 nm/sec (high compound permeability); 4-70 nm/sec (medium permeability); <4 nm/sec (low compound permeability).[14][15] In **Table 2.** it can be seen the absorption of the compound active *methyl ricinoleate* has a value of 1.57 log cm/s which is low permeability. Volume of distribution (VDss) is the ability to interact between the distribution phase and the second phase of pharmacokinetics.[13] A compound can be evenly distributed with the same concentration in blood plasma if the volume of distribution is > 0.45 log L/kg, so it can be seen if the compound *methyl ricinoleate* < 0.45 log L/kg, meaning that it is not evenly distributed in blood plasma.[15] Total clearance is the total elimination of a drug concentration, which is at this clearance the concentration of a drug becomes exhausted or does not exist in the body.[13] It can be seen in **Table 2.** The amount of absorption of the active compound *Bouea macrophylla* G. tested and released was equally large so that the ADME process that took place was balanced.

The 10 active compounds tested *Bouea macrophylla* G. (**Table 2.**) did not act as CYP2D6 inhibitors. Cytochrome P450 is an enzyme that is responsible for the metabolism of a drug. Cytochrome P450 has two main isoforms, namely CYP2D6 and CYP3A4.[15] So if a CYP2D6 inhibitor is found in a compound, it is feared that it will change a drug's pharmacokinetics.

AMES test is a simple way to test the properties of compounds in the form of mutagenic and carcinogenic properties as mutagenic frames.[13],[16] In this study (**Table 2.**) it was found that all tested *Bouea macrophylla* G. compounds were neither mutagenic nor carcinogenic, as was atorvastatin. The safety test of all tested *Bouea macrophylla* G. active compounds was made by determining the acute and chronic lethal doses as Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) (Table 2), respectively. The LD50 of *methyl ricinoleate* compound is 1,573 mol/kg where the LD50 dose of *methyl ricinoleate* compound is smaller than the LD50 of atorvastatin with a value of 2,877 mol/kg. Meanwhile, the LOAEL value of *methyl ricinoleate* is 2,701 log/mg/kg_bw/day, which means it is lower than the LOAEL for atorvastatin with a value of 4.839 log/mg/kg_bw/day [13].

Table 4. shows that the results of docking angiotensin-2 (Ang-2) with 10 tested active compounds *Bouea macrophylla* G. and with atorvastatin resulted in binding affinity varying from -3.3 kcal/mol to -6.5 kcal/mol. The binding affinity value has the potential to predict the strength of the interaction between the ligand and the receptor, the more negative or the smaller the affinity value, the more stable and strong the bond is. So it can be seen that the 10 active compounds tested *Bouea macrophylla* G. have less stable bonds than *atorvastatin* [13], [17].

Hydrogen bonding provides a stronger affinity and plays an important role in stabilizing the structure, so it is very important in the development of drug design. The closer the distance formed in a bond, the stronger the bond and the more significant the activity.[13], [18], [19] Existence of the same residue is very important for the resulting pharmacological effect because the same residue with the reference ligand (comparison drug) is predicted to show activity at the receptor. An active compound is predicted to have a strong bond with the target protein if it is able to bind strongly with hydrogen bonds with the same amino acid residue compared to the control compound (atorvastatin) [20], [21].

Table 4. shows that Tie2 can interact with the Ang-2_ bond of the active leaf compound *Bouea macrophylla* G. and the Ang-2_ *atorvastatin* bond. The presence of protein-to-protein docking interactions is indicated by the amino acid bonds between the ligand and the receptor in the form of hydrogen, hydrophobic, and electrostatic bonds. The type of bond determines the strength of the binding between the drug and the receptor. Bioactive compounds are predicted to have a strong bond with the target receptor if they are able to bind tightly through hydrogen bonds and bind to one amino acid residue from the active site compared to comparison or inhibitor compounds [22]. The result of docking between Tie2_Ang-2_Vitamin E bonds (**Table 4.**) resulted in the type of interaction in the form of electrostatic hydrogen. Electrostatic interactions serve to increase the stability of the ligand to the receptor [23].

Commented [AMJ8]: what does it cover? explain and describe

The binding affinity value of Tie2_Ang-2_ *methyl ricinoleate* bond was more negative than that of Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *atorvastatin* (Table 4.). Although the Ang-2_ *methyl ricinoleate* bond has a weaker binding affinity than the Ang-2_ *atorvastatin* bond, the Ang-2_ *methyl ricinoleate* bond has the same residue as Ang-2_ *atorvastatin* and has one hydrogen bond. Likewise, Tie2_Ang-2_ *methyl ricinoleate* which has the same residues with Tie2_Ang-2_ *atorvastatin* bonds between the results of protein to protein docking with Ang-2 bonds and 10 active compounds Bouea macrophylla G. and has the most hydrogen bonds between protein to protein docking with bonds Ang-2 and 10 active compounds Bouea macrophylla G. and *atorvastatin*. So that it can be seen if the active compound *methyl ricinoleate* has the most stable and best bond compared to the Ang-2_9 bond of the other active compound Bouea macrophylla G. tested. This is in line with the research of Utami et al. (2022) that a good compound is a compound with a negative binding affinity, has a hydrogen bond, and has the same residue with the protein-ligand bond of comparison. In addition, it is necessary to know if hydrophobic bonds which are non-covalent type bond interactions also play an important role in stabilizing proteins, and increasing the inhibitor's affinity for enzymes [13], [24].

The existence of hydrogen bonds is very important in a drug development. The hydrogen bonds shared by Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *methyl ricinoleate* play a key [25] Thus, *methyl ricinoleate* compounds are able to inactivate Ang-2 to block Ang-2/Tie2 signaling as a trigger for inflammation in pathological conditions. The increased expression of Ang-2 under pathological conditions will promote inflammation [26], [27]. During inflammation, Ang-2 is rapidly secreted from the Weibel-Palade body on EC (endothelial cells) and counteracts the vascular stabilizing activity of the Tie2 receptor by blocking its interaction with its canonical agonist ligand, Ang-1. Ang-2 released by exocytosis of WPB (Weibel Palade Body) interferes with the recruitment of pericytes to new blood vessels during angiogenesis by blocking Ang-1/Tie2 autocrine signaling [28]–[30] By inhibiting the Ang-2/Tie2 signaling pathway, vessel-in-vessel growth can be clearly promoted in inflammation. Pericyte coverage which increases after Ang-2 is inhibited will affect the stabilization of new blood vessels. VE-Cad accumulation will decrease and phosphorylation will increase. Therefore, by inhibiting Ang-2, the maturation of blood vessels will increase.[31] In addition, the development of a drug needs to pay attention to good pharmacokinetics, the right balance between hydrophilicity and lipophilicity.[25] One indicator that can be used is Lipinski's Rule of Five. *Methyl ricinoleate* can inhibit pro-inflammatory agents such as carrageenan. Thus, the *methyl ricinoleate* compound is able to inactivate Ang-2 to form the process of blocking the Ang-2/Tie2 signal as a trigger for inflammation in pathological conditions. The effect is as an inhibitor of vasodilation, protein extravasation and edema. Thus, based on the results of the study (Table 1.), the *methyl ricinoleate* compound has been declared to have passed and fulfilled the pharmacokinetic requirements.

5. Conclusion

Based on the results of research that has been carried out, the active compound methyl ricinoleate from Bouea macrophylla G. can potentially be a candidate for anti-inflammatory drugs through inhibition of Ang-2.

Commented [AMJ9]: what is the key role?

6. References

- [1] L. Ram, "Epidemiology and outcomes of traumatic dental injuries: A review of the literature," *Aust Dent J*, vol. 61, 2016.
- [2] A. Antipovienė, J. Narbutaite, and J. Virtanen, "Traumatic Dental Injuries, Treatment and Complications in Children and Adolescents: A Register-Based Study," *euros. J. Dent.*, 2021.
- [3] F. Liu, T. Wu T, and G. Lei, "Worldwide tendency and perspectives in traumatic dental injuries: A bibliometric analysis over two decades (1999-2018)," *Dent Traumatol*, vol. 36, no. 5, 2020.
- [4] A. DiAngelis, J. Andreasen, and K. Ebeleseder, "International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 1. Fractures and luxations of permanent teeth," *Dent Traumatol*, vol. 28, no. 1, 2012.
- [5] Taufiqurrahman I, Dina H. Test of Ethanol Solvent Concentration Variation on Total Flavonoid Level of Ramania (*Bouea Macrophylla* Griffith) Leaf Extract. 2016;000(12):2.
- [6] Rosita JM, Taufiqurrahman I, Edyson. Differences in Total Flavonoids between Maceration and Soxhletation Methods on Ramania (*Bouea macrophylla* Griff) Leaf Extract. *Dentino J Dentist*. 2017;1(1):22-7.
- [7] NH Nguyen, TT Nguyen, PC Ma, QTH Ta, TH Duong, and VG Vo, "Potential antimicrobial and anticancer activities of an ethanol extract from bouea macrophylla," *Molecules*, vol. 25, no. 8, 2020, doi:10.3390/molecules25081996.
- [8] ZX Yan, Y. Luo, and NF Liu, "Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in m(Ram,Rammouse cornea," *int. J. Ophthalmol.*, vol. 10, no. 8, pp. 1187-1194, 2017, doi:10.18240/ijo.2017.08.01.
- [9] AC Mirando, RL E Silva, Z. Chu, PA Campochiaro, NB Pandey, and AS Popel, "Suppression of ocular vascular inflammation through peptide-mediated activation of angiopoietin-tie2 signaling," *int. J. Mol. science.*, vol. 21, no. 14, pp. 1-20, 2020, doi:10.3390/ijms21145142.
- [10] M. Teichert *et al.*, "Pericyte-expressed Tie2 controls angiogenesis and vessel maturation," *Nat. Commun.*, vol. 8, no. May, pp. 1-12, 2017, doi:10.1038/ncomms16106.
- [11] H. Bond and S. Neidle, "Lipinski's Rule of Five Design Principles for Quadruplex-binding Small Molecules," 2019.
- [12] SK Enmozhi, K. Raja, I. Sebastine, and J. Joseph, "Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach," *J. Biomol. Struct. Dyn.*, vol. 0, no. 0, pp. 1-7, 2020, doi:10.1080/07391102.2020.1760136.
- [13] Utami JP, Kurnianingsih N, Faisal MR. An in Silico Study of the Cathepsin L Inhibitory Activity of Bioactive Compounds in *Stachytarpheta jamaicensis* as a Covid-19 Drug Therapy. *Makara J Sci*. 2022;26(1).
- [14] J. Olaleye, O. Moses, and O. Titilope, "Covid-19 treatment: Investigation on the phytochemical constituents of *Vernonia amygdalina* as potential Coronavirus-2 inhibitors," *Comput. Toxicol.*, no. January, 2021.
- [15] A. Kirtishanti, Siswandono, S. Hardjono, and D. Kesuma, "Molecular Docking of Benzoylurea Derivatives as Potential Anti-Breast Cancer Agent and Its Admet Profiles," *J. Glob. Pharma Technol.*, vol. 12, no. 6, pp. 726-735, 2020.

- [16] KH Hsu, BH Su, YS Tu, OA Lin, and YJ Tseng, "Mutagenicity in a molecule: Identification of core structural features of mutagenicity using a scaffold analysis," *PLoS One*, vol. 11, no. 2, p. 2, 2016, doi:10.1371/journal.pone.0148900.
- [17] N. Nursamsiar, MM Mangade, A. Awaluddin, S. Nur, and A. Asnawi, "In Silico Study of Aglycon Curculigoside A and Its Derivatives as α -Amylase Inhibitors," *Indonesia. J. Pharm. science. Technol.*, vol. 7, no. 1, p. 29, 2020, doi:10.24198/ijpst.v7i1.23062.
- [18] Y. Bare, AD Kuki, SSN Daeng Tiring, AH Rophi, GC Krisnamurti, and DR Tirto Sari, "In Silico Study: Prediction of the Potential of Caffeic Acid As ACE inhibitor," *El-Hayah*, vol. 7, no. 3, pp. 94–98, 2020, doi:10.18860/elha.v7i3.10053.
- [19] R. Mutiah, AF Firdausy, YYA Indrawijaya, and H. Hibbatullah, "In Silico Prediction of Heliannuol A, B, C, D, and E Compounds on Estrogen Receptor Agonists," *Indonesia. J. Cancer Chemoprevention*, vol. 12, no. 1, p. 37, 2021, doi:10.14499/indonesianjcanchemoprev12iss1pp37-45.
- [20] Barelrier, T. Sterling, MJ O'Meara, and BK Shoichet, "The Recognition of Identical Ligands by Unrelated Proteins," *ACS Chem Biol*, vol. 176, no. 3, pp. 139–148, 2016, doi:10.1021/acscmbio.5b00683.The.
- [21] Ruswanto R, Mardianingrum R, Lestari T, Nofianti T, Tuslinah L, Nurmalik D. In silico study of the active compounds in bitter melon (*Momordica charantia* L) as antidiabetic medication. *Pharmacy*. 2018;8(2):194.
- [22] DS Damayanti, DH Utomo, and C. Kusuma, "Revealing the potency of *Annona muricata* leaves extract as FOXO1 inhibitor for diabetes mellitus treatment through computational study," *Silicon Pharmacol.*, vol. 5, no. 1, 2017, doi:10.1007/s40203-017-0023-3.
- [23] MJ Yunta, "Docking and Ligand Binding Affinity: Uses and Pitfalls Maria," *Am. J. Models. Optimistic.*, vol. 4, no. January 2016, pp. 74–114, 2016, doi:10.12691/ajmo-4-3-2.
- [24] Ramayanti K, Riza H, Fajriaty I. Molecular Docking of Drymaritin, Triptonine a and Triptonine b Compounds Against HIV Enzymes. *J Mhs Farm Fak Kedokt UNTAN*. 2019.
- [25] T. Coimbra, R. Feghali, R. Ribeiro, M. Ramons, and P. Fernandes, "The Importance of Intramolecular Hydrogen Bonds on The Translocation of The Small Drug Piracetam Through a Lipid Bilayer," *R. Soc. Chem.*, vol. 11, no. 2, p. 89, 2021.
- [26] C. Daly *et al.*, "Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition," *Cancer Res.*, vol. 73, no. 1, pp. 108–118, 2013, doi:10.1158/0008-5472.CAN-12-2064.
- [27] T. Shlamkovich, L. Aharon, WA Barton, and N. Papo, "Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoietin-2 ligands as candidates for antiangiogenesis therapy," *Oncotarget*, vol. 8, no. 20, pp. 33571–33585, 2017, doi:10.18632/oncotarget.16827.
- [28] SM Parikh, "The Angiopoietins and Tie2 in Vascular Inflammation," *HHS Public Access*, vol. 24, no. 5, 2017.
- [29] M. Cossutta *et al.*, "Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis," *Arterioscler. Thromb. Vasc. Biol.*, vol. 39, no. 9, pp. 1843–1858, 2019, doi:10.1161/ATVBAHA.119.313021.
- [30] M. Jeltsch and V. Leppa, "Tyrosine Kinase-Mediated Receptors," pp. 1–22, 2016.

- [31] F. Baganha *et al.*, “Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization,” *Angiogenesis*, vol. 24, no. 3, pp. 567–581, 2021, doi:10.1007/s10456-021-09767-9.



Irham Taufiqurrahman

Correspondence

To: support@azerbaijanmedicaljournal.com, admin@azerbaijanmedicaljournal.com

Sent - ULM 13 June 2023 16:57

Date: 13 June 2023

Title: An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (*Bouea macrophylla* Griffith) Against Angiotensin-2

Sub: Manuscript Submission

Paper ID: AMJ-05-06-2023-11524

Dear, Admin Board Azerbaijan Medical Journal

We hereby send you an article that has been revised. Thank you very much for your attention! We are looking forward to hearing from you soon!

Thank you,
Dr Irham
Corresponding author



An In Silico Study Anti-Inflammatory of Active Compound of *Ramania* Leaves Extract (*Bouea macrophylla* Griffith) Against Angiotensin-2

Irham Taufiqurrahman¹, Isyana Erlita², Mira Hadistina³, Juliyatin Putri Utami⁴, Andi Zulkifli⁵, Veni Hadju⁵, Eko Suhartono⁶, Muhammad Irpan Hendrawan⁷

¹Departement of Oral and Maxillofacial Surgery, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia

²Department of Conservative Dentistry, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia

³Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia

⁴Department of Biomedicine Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia

⁵Faculty of Public Health, Hasanuddin University, Makassar - Indonesia

⁶Department of Medical Chemistry/Biochemistry, Faculty of Medicine, Lambung Mangkurat University, Indonesia

⁷Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia

*Corresponding author : irham.taufiqurrahman@ulm.ac.id

Abstract—Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti and colleagues, the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59%. Purpose: To determine the active compound binding of *Bouea macrophylla* G. (*ramania*) as an anti-inflammatory by inhibiting the protein angiotensin-2 (Ang-2) in silico. Method: Experimental design through in silico method. Result: Methyl ricinoleate compound has RMSD (Root Mean Square Deviation) value of 0 and negative binding affinity value, hydrogen bonding, and the same residue as the comparison ligand, atorvastatin. All active compounds of *Bouea macrophylla* G. has passed the drug likeness test with Lipinski's Rule parameters. Based on the results of the ADMET test, it is known that the absorption of methyl ricinoleate compounds can be absorbed well, the absorption of Caco-2 cells is the highest compared to the 9 active compounds of *Bouea macrophylla* G. and atorvastatin, the volume of distribution and total clearance is better than atorvastatin, does not inhibit CYP50, is not mutagenic, carcinogenic, and not hepatotoxic, has lower Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) values compared to atorvastatin. Conclusion: Methyl ricinoleate can potentially be an anti-inflammatory drug through the inhibition of Ang-2.

Keywords— Angiotensin-2, Anti-inflammatory, *Ramania*.

1. Introduction

Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact [1]. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti et al (2018), the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59% [2], [3]. TDI trauma that occurs often involves many tissues and takes a lot of time to treat, so treatment is relatively expensive and difficult. Some drugs such as antibiotics are also used in addition to surgery [1], [4].

The use of drugs in wound healing is available with various kinds and types, including the use of herbal medicines. Herbal medicine is an alternative in medicine because the price is cheap, the ingredients are relatively easy to obtain and do not cause side effects. *Bouea macrophylla* G. can be selected as a plant that can play a role in accelerating wound healing. It is known that the leaves of *Bouea macrophylla* G. contain compounds of caryophyllene, humulene; hexadecanoic acid, ethyl ester (palmitic acid); phytol; squalene; vitamin E; retinol, acetate; and γ -himachalene which has potential as an anti-inflammatory [5–7].

Treatment of wound healing in soft tissue aims to clean the wound area from foreign objects, dead cells and bacteria so as to support the healing process. As the body's response to wound healing, there is an inflammatory process that involves: a number of endothelial growth factors. One of the proteins derived from endothelial growth factor is the protein angiopoietin-2 (Ang-2). Ang-2 is the second member of the angiopoietin family that plays a role in blood formation and is known as a protein ligand and is secreted from the receptor tyrosine kinase (Tie2). Ang-2 acts as a vascular disruptor which is its role as a natural Tie2 antagonist by counteracting the vascular-stabilizing activity of the Tie2 receptor while simultaneously blocking its interaction with its canonical agonist ligand, Ang-1 during inflammation. Thus, when the Ang-2/Tie2 signaling pathway is inhibited, vessel-in-vessel growth can be markedly enhanced in inflammation and new fields can be discovered for therapeutic exploration [6, 8–10].

The comparison ligand used was an Ang-2 inhibitor, namely atorvastatin. The comparison protein used in protein-to-protein docking is Tyrosine Kinase-2 (Tie2). This study predicts the therapeutic target for Ang-2 by using 10 active compounds *Bouea macrophylla* G.

2. Materials & method

2.1 Ligand and Protein Preparation

Receptors namely Ang-2 and Tie2 were prepared using Biovia Discovery Studio version 21 application to remove water molecules and residues. The ligands, namely the active compound *Bouea macrophylla* G. and atorvastatin, were prepared using the Open Babel program from PyRx version 0.8 to minimize energy, optimize, and convert the format to .pdb.

2.2 Validation

The validation process was carried out by re-docking the Ang-2 protein with its natural ligand (calcium ion) (CID:336285734). The parameter used is the RMSD (Root Mean Square Deviation) value. The validation results obtained are 0. RMSD is a value associated with the deviation of the binding position. The docking method is said to be valid if the RMSD value is 2, so the docking method can be used for the docking test of active compounds.

2.3 Protein-Ligand Docking and Visualization

Molecular docking simulation using AutoDock Vina program which is integrated with PyRx version 0.8. The analysis and visual prediction of the protein-ligand complex virtual from the docking stage were analyzed and visualized using the Biovia Discovery Studio version 21 application. The interaction side was analyzed based on the residual ligand interaction and structural conformation. Ang-2 was also docked with atorvastatin to compare the binding affinity values of 10 *Bouea macrophylla* G compounds.

2.4 Prediction of drug-likeness, pharmacokinetics, and safety

Lipinski's Rule of 5 used to predict drug similarity to the active compound, which was evaluated by the pkCSM website (<http://biosig.unimelb.edu.au/pkcsm/prediction>) and PubChem (<https://pubchem.ncbi.nlm.nih.gov/>).

3. Results

In **Table 1**, it can be seen that the highest molecular weight is owned by atorvastatin with a weight of 558.65 g/mol and the lowest weight is a compound of humulene and a compound of γ -himachalene with a weight of 204.357 g/mol. The best logP values were owned by *carophyllene* compounds and γ -himachalene compounds with a logP of 4.7252. While the largest is squalene compound with logP 10,605. All of the active compounds have good hydrogen acceptors, *Bouea macrophylla* G. Meanwhile, all of the tested active compounds of *Bouea macrophylla* G. have < 5 . The widest topological polar surface area (TPSA) (Table 1) is owned by atorvastatin compounds with an area of 112. Based on Table 1, it was found that all active compounds of *Bouea macrophylla* G. leaf extract passed the Lipinski's rules test.

All the active compounds of *Bouea macrophylla* G. tested (**Table 2**) were well absorbed in the human intestine. The highest absorption of Caco-2 cells was methyl ricinoleate with a value of 1.57 log cm/s. The highest VDss value was found in vitamin E compounds with a VDss value of 0.873 log L/kg.

The 10 active compounds tested *Bouea macrophylla* G. (**Table 2**) did not act as CYP2D6 inhibitors, so their pharmacokinetic properties were enzymatic. The highest total clearance value was owned by *squalane* compound with a value of 1.791 log mL/minute/kg.

All tested *Bouea macrophylla* G. compounds were neither mutagenic nor carcinogenic, nor was atorvastatin. In the hepatotoxicity test (Table 2.), it was found that all *Bouea macrophylla* G. compounds were not hepatotoxic, except for the retinol compound, acetate, which resulted in hepatotoxicity as well as *atorvastatin*. The highest LD50 is owned by atorvastatin with a value of 2.877 mol/kg. The highest LOAEL was owned by *atorvastatin* with a value of 4.839 mol/kg.

Table 3. The binding affinity value obtained varies from -3.3 kcal/mol to -6.5 kcal/mol. The lowest bond value was owned by the Ang-2_atorvastatin bond of -6.5 kcal/mol. While the highest is the Ang-2_palmitic acid bond. Ang-2_Bond Methyl ricinoleate has 2 hydrogen bonds. In addition, the Ang-2_methyl ricinoleate bond has the same residue as the Ang-2_atorvastatin bond residue, namely the GLU35 residue. The result of Ang-2_pristanal docking also has 2 hydrogen bond interactions. Meanwhile, Ang-2_retinol, acetate; Ang-2_phytol; and Ang-2_palmitic acid has a hydrogen bond type interaction, while the Ang-2_ γ -himachlene bond; Ang-2_vitamin E bond; bond Ang-2_carophyllene; bond Ang-2_humulene; Ang-2_squalene bonds have no hydrogen-type bond interactions.

The most negative binding affinity value from the results of docking to protein (Table 4.) is the result of docking tyrosine kinase-2 (Tie2) with Ang-2_carophyllene bonds with a value of -8.1 kcal/mol, higher than the binding affinity value of Tie2_Ang-2_atorvastatin with a value of -7.5 kcal/mol. While the highest is Tie2_Ang-2_palmitic acid with a value of -4 kcal/mol.

The amino residues on the interaction bonds found in the protein-to-protein docking results (**Table 4**.) were almost all similar to the amino acid residues from the docking of Ang-2 with the active compounds *Bouea macrophylla* G. and *atorvastatin*, except for the docking results of Tie2_Ang-2_pristanal at residues MET857 and PHE869, Tie2_Ang-2_methyl ricinoleate. Tie2_Ang-2_methyl ricinoleate has the same residues with a total of 12 residues that are the same as Tie2_Ang-2_atorvastatin, namely at residues LYS855, ARG856, VAL829, LEU839.

Hydrogen bond interactions from protein to protein docking results (**Table 4**.) from Tie2_Ang-2_10 active compound *Bouea macrophylla* G. and Tie2_Ang-2_atorvastatin bonds were mostly found in Tie2_Ang-2_atorvastatin bonds with 5 hydrogen bonds at residues LYS855, ARG856, LYS858 and bonds Tie2_Ang-2_methyl ricinoleate on residues LYS855, ARG856 (3.25349 and 3, 37493), GLN837, and CO. Meanwhile, the Tie2_Ang-2_carophyllene bond, the Tie2_Ang-2_pristanal bond, the Tie2_Ang-2_humulene bond, and the Tie2_Ang-2_ γ -himachlene bond did not have hydrogen bonds.

Table 1. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand Atorvastatin Correlation with Lipinski's Rule.

Compound	Molecular Weight (g/mol)	LogP	Hydrogen Acceptors (n)	Hydrogen Donor (n)	TPSA (Topological Polar Surface Area)	Lipinski's Law Deviations	Pass/No
<i>Carophyllene</i>	204.537	4.7252	0	0	0	0	Graduated
<i>2-Methyl-cis-7, 8-epoxy-nonadecane (Pristanal)</i>	296.539	6.8911	1	0	12.5	1	Graduated
<i>Humulene</i>	204,357	5.0354	0	0	0	1	Graduated
<i>Hexadecanoic acid, ethyl ester (Palmitic acid)</i>	284,484	6.1884	1	1	37.3	1	Graduated
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans- (Methyl ricinoleate)</i>	312,494	5.5673	2	1	46.5	1	Graduated
<i>Phytol</i>	296.539	6.3641	1	1	20.2	1	Graduated
<i>Retinol, Acetate</i>	328,496	6.0811	2	0	26.3	1	Graduated
Vitamin E	430.717	8.8402 6	2	1	29.5	1	Graduated
<i>γ-himachalene</i>	204,357	4.7252	0	0	0	0	Graduated
<i>Squalene</i>	410.73	10,605	0	0	0	1	Graduated
<i>Atorvastatin</i>	558.65	6,3136	5	4	112	2	Graduated

Table 2. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand Atorvastatin

Compound	Caco-2 permeability (nm.sec ⁻¹)	Human Intestinal Absorption (%)	VD _{ss} (log L/kg)	CYP 2D6 Inhibitor	Total Clearance	AMES Toxicity	Hepatotoxicity	Oral Rate Acute Toxicity (LD50) (mol/kg)	Oral Rate Chronic Toxicity (LOAEL) (log mg/kg_bw/day)
<i>Carophyllene</i>	1.434	95.304	0.653	No	1.088	No	No	1,678	1.44
<i>2-Methyl-cis-7, 8-epoxynonadecane</i>	1.32	91,567	0.451	No	1,631	No	No	1.382	1.028
<i>Humulene</i>	1.421	94,682	0.505	No	1,282	No	No	1,766	1.336
<i>Hexadecanoic acid, ethyl ester</i>	1.38	92,158	-0.679	No	1,678	No	No	1.46	3.298
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-</i>	1.57	91,956	-0.509	No	1.615	No	No	1.573	2,701
<i>Phytol</i>	1.487	89,892	0.416	No	1,686	No	No	1,646	1.024
<i>Retinol, Acetate</i>	1.188	94.33	0.408	No	1.503	No	Yes	1,673	2.276
Vitamin E	1,215	90,045	0.873	No	0.801	No	No	2,243	2.445
<i>γ-himachalene</i>	1.418	94.556	0.648	No	1.093	No	No	1,681	1.346
<i>Squalene</i>	1.193	89,581	0.282	No	1,791	No	No	1995	0.902
<i>Atorvastatin</i>	0.23	59,861	-1.918	No	0.437	No	Yes	2.877	4.839

Table 3. Results of Docking Ang-2 with Bouea macrophylla G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-5.3	ILE309, LYS310	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxynonadecane</i> (Pristanal)	-4.2	GLY347, GLY345	<i>hydrogen</i>
		LYS310, VAL344, ILE309, PRO349, LYS340	<i>Hydrophobic</i>
<i>Humulene</i>	-4.8	-	-
<i>Hexadecanoic acid, ethyl ester</i> (Palmitic acid)	-3.3	PHE346	<i>hydrogen</i>
		ILE309, VAL344, LYS310	<i>Hydrophobic</i>
<i>*Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-(Methyl ricinoleate)</i>	-4.5	GLU395, *GLU358	<i>hydrogen</i>
		PRO303	<i>Hydrophobic</i>
<i>Phytol</i>	-4	GLU308	<i>hydrogen</i>
		LYS310	<i>Unfavorable</i>
		PRO349, ILE309, VAL344	<i>Hydrophobic</i>
		LYS372	<i>hydrogen</i>
<i>Retinol, Acetate</i>	-5.7	ALA494, VAL370, LEU386	<i>Hydrophobic</i>
		PHE469, PRO452, PHE469, PHE469, TYR475, TYR475	<i>Hydrophobic</i>
<i>γ-himachalene</i>	-5.8	MET458	<i>Hydrophobic</i>
<i>Squalene</i>	-4.4	ILE309, LYS310, PRO349, VAL344, VAL344	<i>Hydrophobic</i>
<i>Atorvastatin</i>	-6.5	SER393, TYR391	<i>hydrogen</i>
		*GLU358, *GLU358	<i>Halogen</i>
		ASN365, HIS402	<i>Unfavorable</i>

* =The same residue as the comparison ligand




Figure 1. a. 3D Structure of Ang-2 docked with Oxiraneundecanoic acid, 3-penthyl-methyl ester, trans-(methyl ricinoleate), b. 2D structure of Ang-2 docked with Oxiraneundecanoic acid, 3-penthyl-methyl ester, trans-(methyl ricinoleate)




Figure 2. a. 3D structure of Ang-2 docked with Atorvastatin, b. 2D structure of Ang-2 docked with Atorvastatin

Table 4. Results of Docking Tie2_Ang-2 with Bouea macrophylla G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-8.1	*VAL829	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxynonadecane (Pristanal)</i>	-4.7	*VAL829, *VAL829, *VAL829, *ARG856, *ARG856, *LYS858 *LYS858, MET857, *LEU839, *LEU839, *ARG856, *VAL829, PHE869	<i>Hydrophobic</i>
<i>Humulene</i>	-7.9	VAL829	<i>Hydrophobic</i>
<i>Hexadecanoic acid, ethyl ester (palmitic acid)</i>	-4	*LYS855, *ARG856 *VAL829, *VAL829, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-(Methyl ricinoleate)</i>	-5.6	*LYS855, *ARG856, GLN837, *ARG856, CO, *VAL829, *VAL829, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Phytol</i>	-5	*ARG856 *VAL829, *VAL829, *LEU839, *LYS858, *LYS858	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Retinol, Acetate</i>	-6.7	THR1016, ASN1018 TYR1012, TYR992, VAL1014, TYR1012	<i>hydrogen</i> <i>Hydrophobic</i>
Vitamin E	-6.8	*LYS855 *VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrogen Bond;</i> <i>Electrostatic</i> <i>Hydrophobic</i>
<i>γ-himachalene</i>	-7.1	*VAL829, *LEU839, *ARG856, *VAL829, *VAL829, *LEU839	<i>Hydrophobic</i>
<i>Squalene</i>	-4.8	LYS1059, LEU1061, ALA1114, LYS1059, TYR1068, TYR1068	<i>Hydrophobic</i>
Atorvastatin	-7.5	*LYS855, *ARG856, *LYS858, *ARG856 *LYS855 *LEU839, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrogen Bond</i> <i>Hydrogen Bond;</i> <i>Electrostatic</i> <i>Hydrophobic</i>




Figure 3. a. Result 3D Structure Docking Protein Tie2_Ang-2 with *Methyl Ricinoleate*, b. 2D Structure of Tie2_Ang-2 Protein Docking Result with *Methyl Ricinoleate*




Figure 4. a. Result 3D Structure of Docking Protein Tie2_Ang-2 with *Atorvastatin*, b. 2D Structure of Tie2_Ang-2 Protein Docking Results with *Atorvastatin*

4. Discussion

Table 1. All active compounds of *Bouea macrophylla* G. can be potential candidates for oral drugs because all active compounds of *Bouea macrophylla* G. leaves passed the Lipinski test. Neidle et al. (2019) stated that good absorption is absorption that meets 3 or more Lipinski's rules which include: molecular weight not more than 500 g/mol, number of H-bond acceptors not more than 10, Number of H-bond donors not more than 5, and LogP not more than 5 (or MlogP > 5) [11], [12].

In the pharmacokinetic test results (Table 2.), all tested active compounds of *Bouea macrophylla* G. were well absorbed in the human intestine, because the percentage absorption of all tested compounds was >89%. Based on Utami et al. (2022), the value of good absorption in the human intestine is 70-100% [13][14].

Caco-2 cells are permeability parameters used to determine drug transport through specialized epithelium derived from human colonic adenocarcinoma which has multiple transport pathways. The parameter categories of Caco-2 cells were >70 nm/sec (high compound permeability); 4-70 nm/sec (medium permeability); <4 nm/sec (low compound permeability).[14][15] In **Table 2.** it can be seen the absorption of the compound active *methyl ricinoleate* has a value of 1.57 log cm/s which is low permeability. Volume of distribution (VD_{ss}) is the ability to interact between the distribution phase and the second phase of pharmacokinetics.[13] A compound can be evenly distributed with the same concentration in blood plasma if the volume of distribution is > 0.45 log L/kg, so it can be seen if the compound *methyl ricinoleate* < 0.45 log L/kg, meaning that it is not evenly distributed in blood plasma.[15] Total clearance is the total elimination of a drug concentration, which is at this clearance the concentration of a drug becomes exhausted or does not exist in the body.[13] It can be seen in **Table 2.** The amount of absorption of the active compound *Bouea macrophylla* G. tested and released was equally large so that the ADME process that took place was balanced.

The 10 active compounds tested *Bouea macrophylla* G. (**Table 2.**) did not act as CYP2D6 inhibitors. Cytochrome P450 is an enzyme that is responsible for the metabolism of a drug. Cytochrome P450 has two main isoforms, namely CYP2D6 and CYP3A4.[15] So if a CYP2D6 inhibitor is found in a compound, it is feared that it will change a drug's pharmacokinetics.

AMES test is a simple way to test the properties of compounds in the form of mutagenic and carcinogenic properties as mutagenic frames.[13],[16] In this study (**Table 2.**) it was found that all tested *Bouea macrophylla* G. compounds were neither mutagenic nor carcinogenic, as was atorvastatin. The safety test of all tested *Bouea macrophylla* G. active compounds was made by determining the acute and chronic lethal doses as Oral Rate Acute Toxicity (LD₅₀) and Oral Rate Chronic Toxicity (LOAEL) (Table 2), respectively. The LD₅₀ of *methyl ricinoleate* compound is 1,573 mol/kg where the LD₅₀ dose of *methyl ricinoleate* compound is smaller than the LD₅₀ of atorvastatin with a value of 2,877 mol/kg. Meanwhile, the LOAEL value of *methyl ricinoleate* is 2,701 log/mg/kg_bw/day, which means it is lower than the LOAEL for atorvastatin with a value of 4.839 log/mg/kg_bw/day [13].

Table 4. shows that the results of docking angiotensin-2 (Ang-2) with 10 tested active compounds *Bouea macrophylla* G. and with atorvastatin resulted in binding affinity varying from -3.3 kcal/mol to -6.5 kcal/mol. The binding affinity value has the potential to predict the strength of the interaction between the ligand and the receptor, the more negative or the smaller the affinity value, the more stable and strong the bond is. So it can be seen that the 10 active compounds tested *Bouea macrophylla* G. have less stable bonds than *atorvastatin* [13], [17].

Hydrogen bonding provides a stronger affinity and plays an important role in stabilizing the structure, so it is very important in the development of drug design. The closer the distance formed in a bond, the stronger the bond and the more significant the activity.[13], [18], [19] Existence of the same residue is very important for the resulting pharmacological effect because the same residue with the reference ligand (comparison drug) is predicted to show activity at the receptor. An active compound is predicted to have a strong bond with the target protein if it is able to bind strongly with hydrogen bonds with the same amino acid residue compared to the control compound (atorvastatin) [20], [21].

Table 4. shows that Tie2 can interact with the Ang-2_ bond of the active leaf compound *Bouea macrophylla* G. and the Ang-2_ *atorvastatin* bond. The presence of protein-to-protein docking interactions is indicated by the amino acid bonds between the ligand and the receptor in the form of hydrogen, hydrophobic, and electrostatic bonds. The type of bond determines the strength of the binding between the drug and the receptor. Bioactive compounds are predicted to have a strong bond with the target receptor if they are able to bind tightly through hydrogen bonds and bind to one amino acid residue from the active site compared to comparison or inhibitor compounds [22]. The result of docking between Tie2_Ang-2_Vitamin E bonds (**Table**

4.) resulted in the type of interaction in the form of electrostatic hydrogen. Electrostatic interactions serve to increase the stability of the ligand to the receptor [23].

The binding affinity value of Tie2_Ang-2_ *methyl ricinoleate* bond was more negative than that of Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *atorvastatin* (**Table 4.**). Although the Ang-2_ *methyl ricinoleate* bond has a weaker binding affinity than the Ang-2_ *atorvastatin* bond, the Ang-2_ *methyl ricinoleate* bond has the same residue as Ang-2_ *atorvastatin* and has one hydrogen bond. Likewise, Tie2_Ang-2_ *methyl ricinoleate* which has the same residues with Tie2_Ang-2_ *atorvastatin* bonds between the results of protein to protein docking with Ang-2 bonds and 10 active compounds *Bouea macrophylla* G. and has the most hydrogen bonds between protein to protein docking with bonds Ang-2 and 10 active compounds *Bouea macrophylla* G. and *atorvastatin*. So that it can be seen if the active compound *methyl ricinoleate* has the most stable and best bond compared to the Ang-2_9 bond of the other active compound *Bouea macrophylla* G. tested. This is in line with the research of Utami et al. (2022) that a good compound is a compound with a negative binding affinity, has a hydrogen bond, and has the same residue with the protein-ligand bond of comparison. In addition, it is necessary to know if hydrophobic bonds which are non-covalent type bond interactions also play an important role in stabilizing proteins, and increasing the inhibitor's affinity for enzymes [13], [24].

The existence of hydrogen bonds is very important in a drug development. The hydrogen bonds shared by Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *methyl ricinoleate* play a key role in molecular recognition, structural stability, enzyme catalysis, drug partitioning and permeability.[25] Thus, *methyl ricinoleate* compounds are able to inactivate Ang-2 to block Ang-2/Tie2 signaling as a trigger for inflammation in pathological conditions. The increased expression of Ang-2 under pathological conditions will promote inflammation [26], [27]. During inflammation, Ang-2 is rapidly secreted from the Weibel-Palade body on EC (endothelial cells) and counteracts the vascular stabilizing activity of the Tie2 receptor by blocking its interaction with its canonical agonist ligand, Ang-1. Ang-2 released by exocytosis of WPB (Weibel Palade Body) interferes with the recruitment of pericytes to new blood vessels during angiogenesis by blocking Ang-1/Tie2 autocrine signaling.[28]–[30] By inhibiting the Ang-2/Tie2 signaling pathway, vessel-in-vessel growth can be clearly promoted in inflammation. Pericyte coverage which increases after Ang-2 is inhibited will affect the stabilization of new blood vessels. VE-Cad accumulation will decrease and phosphorylation will increase. Therefore, by inhibiting Ang-2, the maturation of blood vessels will increase.[31] In addition, the development of a drug needs to pay attention to good pharmacokinetics, the right balance between hydrophilicity and lipophilicity.[25] One indicator that can be used is Lipinski's Rule of Five. *Methyl ricinoleate* can inhibit pro-inflammatory agents such as carrageenan. Thus, the *methyl ricinoleate* compound is able to inactivate Ang-2 to form the process of blocking the Ang-2/Tie2 signal as a trigger for inflammation in pathological conditions. The effect is as an inhibitor of vasodilation, protein extravasation and edema. Thus, based on the results of the study (**Table 1.**), the *methyl ricinoleate* compound has been declared to have passed and fulfilled the pharmacokinetic requirements.

5. Conclusion

Based on the results of research that has been carried out, the active compound methyl ricinoleate from *Bouea macrophylla* G. can potentially be a candidate for anti-inflammatory drugs through inhibition of Ang-2.

6. References

- [1] L. Ram, "Epidemiology and outcomes of traumatic dental injuries: A review of the literature," *Aust Dent J*, vol. 61, 2016.
- [2] A. Antipovienė, J. Narbutaite, and J. Virtanen, "Traumatic Dental Injuries, Treatment and Complications in Children and Adolescents: A Register-Based Study," *euros. J. Dent.*, 2021.
- [3] F. Liu, T. Wu T, and G. Lei, "Worldwide tendency and perspectives in traumatic dental injuries: A bibliometric analysis over two decades (1999-2018)," *Dent Traumatol*, vol. 36, no. 5, 2020.
- [4] A. DiAngelis, J. Andreasen, and K. Ebeleseder, "International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 1. Fractures and luxations of permanent teeth," *Dent Traumatol*, vol. 28, no. 1, 2012.
- [5] Taufiqurrahman I, Dina H. Test of Ethanol Solvent Concentration Variation on Total Flavonoid Level of Ramania (*Bouea Macrophylla* Griffith) Leaf Extract. 2016;000(12):2.
- [6] Rosita JM, Taufiqurrahman I, Edyson. Differences in Total Flavonoids between Maceration and Soxhletation Methods on Ramania (*Bouea macrophylla* Griff) Leaf Extract. *Dentino J Dentist*. 2017;1(1):22–7.
- [7] NH Nguyen, TT Nguyen, PC Ma, QTH Ta, TH Duong, and VG Vo, "Potential antimicrobial and anticancer activities of an ethanol extract from bouea macrophylla," *Molecules*, vol. 25, no. 8, 2020, doi:10.3390/molecules25081996.
- [8] ZX Yan, Y. Luo, and NF Liu, "Blockade of angiopoietin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in m(Ram,Rammouse cornea," *int. J. Ophthalmol.*, vol. 10, no. 8, pp. 1187–1194, 2017, doi:10.18240/ijo.2017.08.01.
- [9] AC Mirando, RL E Silva, Z. Chu, PA Campochiaro, NB Pandey, and AS Popel, "Suppression of ocular vascular inflammation through peptide-mediated activation of angiopoietin-tie2 signaling," *int. J. Mol. science.*, vol. 21, no. 14, pp. 1–20, 2020, doi:10.3390/ijms21145142.
- [10] M. Teichert *et al.*, "Pericyte-expressed Tie2 controls angiogenesis and vessel maturation," *Nat. Commun.*, vol. 8, no. May, pp. 1–12, 2017, doi:10.1038/ncomms16106.
- [11] H. Bond and S. Neidle, "Lipinski's Rule of Five Design Principles for Quadruplex-binding Small Molecules," 2019.
- [12] SK Enmozhi, K. Raja, I. Sebastine, and J. Joseph, "Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach," *J. Biomol. Struct. Dyn.*, vol. 0, no. 0, pp. 1–7, 2020, doi:10.1080/07391102.2020.1760136.
- [13] Utami JP, Kurnianingsih N, Faisal MR. An in Silico Study of the Cathepsin L Inhibitory Activity of Bioactive Compounds in *Stachytarpheta jamaicensis* as a Covid-19 Drug Therapy. *Makara J Sci*. 2022;26(1).
- [14] J. Olaleye, O. Moses, and O. Titilope, "Covid-19 treatment: Investigation on the phytochemical constituents of *Vernonia amygdalina* as potential Coronavirus-2 inhibitors," *Comput. Toxicol.*, no. January, 2021.
- [15] A. Kirtishanti, Siswandono, S. Hardjono, and D. Kesuma, "Molecular Docking of Benzoylurea Derivatives as Potential Anti-Breast Cancer Agent and Its Admet Profiles," *J. Glob. Pharma Technol.*, vol. 12, no. 6, pp. 726–735, 2020.

- [16] KH Hsu, BH Su, YS Tu, OA Lin, and YJ Tseng, "Mutagenicity in a molecule: Identification of core structural features of mutagenicity using a scaffold analysis," *PLoS One*, vol. 11, no. 2, p. 2, 2016, doi:10.1371/journal.pone.0148900.
- [17] N. Nursamsiar, MM Mangade, A. Awaluddin, S. Nur, and A. Asnawi, "In Silico Study of Aglycon Curculigoside A and Its Derivatives as -Amylase Inhibitors," *Indonesia. J. Pharm. science. Technol.*, vol. 7, no. 1, p. 29, 2020, doi:10.24198/ijpst.v7i1.23062.
- [18] Y. Bare, AD Kuki, SSN Daeng Tiring, AH Rophi, GC Krisnamurti, and DR Tirto Sari, "In Silico Study: Prediction of the Potential of Caffeic Acid As ACE inhibitor," *El-Hayah*, vol. 7, no. 3, pp. 94–98, 2020, doi:10.18860/elha.v7i3.10053.
- [19] R. Mutiah, AF Firdausy, YYA Indrawijaya, and H. Hibbatullah, "In Silico Prediction of Heliannuol A, B, C, D, and E Compounds on Estrogen Receptor Agonists," *Indonesia. J. Cancer Chemoprevention*, vol. 12, no. 1, p. 37, 2021, doi:10.14499/indonesianjcanchemoprev12iss1pp37-45.
- [20] Barelier, T. Sterling, MJ O'Meara, and BK Shoichet, "The Recognition of Identical Ligands by Unrelated Proteins," *ACS Chem Biol*, vol. 176, no. 3, pp. 139–148, 2016, doi:10.1021/acscchembio.5b00683.The.
- [21] Ruswanto R, Mardianingrum R, Lestari T, Nofianti T, Tuslinah L, Nuralik D. In silico study of the active compounds in bitter melon (*Momordica charantia* L) as antidiabetic medication. *Pharmacy*. 2018;8(2):194.
- [22] DS Damayanti, DH Utomo, and C. Kusuma, "Revealing the potency of *Annona muricata* leaves extract as FOXO1 inhibitor for diabetes mellitus treatment through computational study," *Silicon Pharmacol.*, vol. 5, no. 1, 2017, doi:10.1007/s40203-017-0023-3.
- [23] MJ Yunta, "Docking and Ligand Binding Affinity: Uses and Pitfalls Maria," *Am. J. Models. Optimistic.*, vol. 4, no. January 2016, pp. 74–114, 2016, doi:10.12691/ajmo-4-3-2.
- [24] Ramayanti K, Riza H, Fajriaty I. Molecular Docking of Drymaritin, Triptonine a and Triptonine b Compounds Against HIV Enzymes. *J Mhs Farm Fak Kedokt UNTAN*. 2019.
- [25] T. Coimbra, R. Feghali, R. Ribeiro, M. Ramons, and P. Fernandes, "The Importance of Intramolecular Hydrogen Bonds on The Translocation of The Small Drug Piracetam Through a Lipid Bilayer," *R. Soc. Chem.*, vol. 11, no. 2, p. 89, 2021.
- [26] C. Daly *et al.*, "Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition," *Cancer Res.*, vol. 73, no. 1, pp. 108–118, 2013, doi:10.1158/0008-5472.CAN-12-2064.
- [27] T. Shlamkovich, L. Aharon, WA Barton, and N. Papo, "Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoietin-2 ligands as candidates for antiangiogenesis therapy," *Oncotarget*, vol. 8, no. 20, pp. 33571–33585, 2017, doi:10.18632/oncotarget.16827.
- [28] SM Parikh, "The Angiopoietins and Tie2 in Vascular Inflammation," *HHS Public Access*, vol. 24, no. 5, 2017.
- [29] M. Cossutta *et al.*, "Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis," *Arterioscler. Thromb. Vasc. Biol.*, vol. 39, no. 9, pp. 1843–1858, 2019, doi:10.1161/ATVBAHA.119.313021.
- [30] M. Jeltsch and V. Leppa, "Tyrosine Kinase-Mediated Receptors," pp. 1–22, 2016.

- [31] F. Baganhaet *al.*, “Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization,” *Angiogenesis*, vol. 24, no. 3, pp. 567–581, 2021, doi:10.1007/s10456-021-09767-9.



Your paper has been accepted

Azerbaijan Medical Journal

Date: 15 Jun 2023
Sub: Paper Accepted
Paper ID: **AMJ-05-06-2023-11524**

Dear Dr. **Irham**,

Thank you for Submitting your manuscript into **Azerbaijan Medical Journal**. We are Pleased and honored to inform you that your paper "**An In Silico Study Anti-Inflammatory of Active Compound of Rhamnus Leaves Extract (Bouea macrophylla Griffith) Against Angiotensin-2**" has been accepted by our Editorial board for the next issue of Azerbaijan Medical Journal.

The current condition of the paper is fully ok and need no further edit for the publications. The editor is really pleased to see this kind of paper and the research applications. In order to proceed for publication, kindly send the Application process charge of the publication within 7 days and submit the completed copyright Agreement paper into your Author Dashboard or through the mail. you can submit it as soon as your payment is done.

If you have any query, Please do not hesitate to mail us. Please fill your paper ID in to the subject of the mail for further inquiry. We eagerly await your response.

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to

support@azerbaijanmedicaljournal.com and related documents mail to

admin@azerbaijanmedicaljournal.com



Your payment has been successful!

Azerbaijan Medical Journal

Date: 16 Jun 2023
Sub: Your payment has been successful!
Paper ID: **AMJ-05-06-2023-11524**

Dear Dr. **Dear Irham**,
Your payment has been successfully done!

Paper ID: AMJ-05-06-2023-11524

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to

support@azerbaijanmedicaljournal.com and related documents mail to

admin@azerbaijanmedicaljournal.com

Azerbaijan Medical Journal

Copyright Transfer Agreement

Paper id: AMJ-05-06-2023-11524

Title of the manuscript: An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (*Bouea macrophylla* Griffith) Against Angiopoietin-2

Journal Name
Azerbaijan Medical Journal

Type of Manuscript: (Research/Review): Research

Author(s) name(s) : Irham Taufiqurrahman, Isyana Erlita, Mira Hadistina, Juliyatin Putri Utami, Andi Zulkifli, Veni Hadju, Eko Suhartono, Muhammad Irfan Hendrawan

Corresponding Author's name, address, affiliation and e-mail: Irham Taufiqurrahman, Faculty of Dentistry Lambung Mangkurat University, irham.taufiqurrahman@ulm.ac.id

The transfer of copyright gives **Azerbaijan Medical Journal** the right to develop, promote, distribute, sell, and archive a body of scientific works throughout the world. The Author hereby grants and assigns to **AMJ** all rights in and to Author's work in and contributions to the Work. In connection with this assignment, the Author acknowledges that **AMJ** will have the right to print, publish, create derivative works, and sell the Work throughout the world, all rights in and to all revisions or versions or subsequent editions of the Work in all languages and media throughout the world. The author(s), reserve the following rights:

All proprietary rights other than copyrights, such as patent rights,
The right to use all or part of this article, including tables and figures in the future works of their own, provided that the proper acknowledgment is made to the Publisher as copyright holder, and

The right to make copies of this article for his/her own use, but not for sale

I warrant and represent that the work does not violate any proprietary or personal rights of others (including, without limitation, any copyrights or privacy rights); that the Work is factually accurate and contains no matter libelous or otherwise unlawful; that I have substantially participated in the creation of the Work and that it represents my original work sufficient for me to claim authorship. I further warrant and represent that I have no financial interest in the subject matter of the Work or any affiliation with an organization or entity with a financial interest in the subject matter of the Work, other than as previously disclosed to the Association.

I have the consent of each author to transfer and assign any and all right, title, and interest, including copyright of the article referenced above. I hereby assign and transfer to the **AMJ copyright** and all rights under it. I further confirm that this article has not been published elsewhere, nor is it under consideration by any other publisher.

Signature:



Date: 16 June 2023



Congratulations! Your paper has been Published.

Azerbaijan Medical Journal

Date: 01 Jul 2023
Sub: Congratulations! Your Paper has been Published
Paper ID: **AMJ-05-06-2023-11524**

Note: Your paper will be automatically updated in scopus by 30 September,2023. authors don't need to do anything as we ourselves will upload papers manually.

Dear Dr. **Irham**,

We are very pleased to inform you that your paper "**An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (Bouea macrophylla Griffith) Against Angiopoietin-2**" has been successfully gone through for all procedure to the publication in "**Azerbaijan Medical Journal**". Your paper has been published and now you can see it and refer it for your further research.

For preventing data breach from aimbot and third party we have secured your data. You will need an access key to see and download your paper. you can see your access key in your Author dashboard. Please share this with your co-authors so that they can also download.

We hope you to publish with your near future.

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to support@azerbaijanmedicaljournal.net and related documents mail to admin@azerbaijanmedicaljournal.net

Azerbaijan Medical Journal, Azerbaijan © 2021 All rights reserved.
Don't like these emails? [Unsubscribe](#).



DASHBOARD

Home Page

Irham

SUBMISSION

- Submissions
- New Submit

Submission Guideline

Show 10 entries

Search:

#SL#	Paper ID	OTP Code	Paper Title	Date	Status	Payment	Action
1	AMJ-05-06-2023-11524	AMJ83517711524	An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (Bouea macrophylla Griffith) Against Angiopoietin-2	05 Jun 2023	Published		



SUBMISSION

Submissions

New Submit

Submission Guideline

Branch / Journal

Azerbaijan Medical Journal

Paper Type

Research Article

Paper Title

An In Silico Study Anti-Inflammatory of Active Compound of Ramanian Leaves Extract (*Bouea macrophylla* Griffith) Against Angiotensin-2

Area of Research

Public Health, Dentistry, Oral and Maxillofacial Surgery, Herbal Medicine, Biochemistry

Paper Issue

35. Issue. 06 - Volume. 63

Abstract

Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti and colleagues, the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59%. To determine the active compound binding of *Bouea macrophylla* G. (*ramania*) as an anti-inflammatory by inhibiting the protein angiotensin-2 (Ang-2) in silico. Experimental design through in silico method. Methyl ricinoleate compound has RMSD (Root Mean Square Deviation) value of 0 and negative binding affinity value, hydrogen bonding, and the same residue as the comparison ligand, atorvastatin. All active compounds of *Bouea macrophylla* G. has passed the drug likeness test with Lipinski's Rule parameters. Based on the results of the ADMET test, it is known that the absorption of methyl ricinoleate compounds can be absorbed well, the absorption of Caco-2 cells is the highest compared to the 9 active compounds of *Bouea macrophylla* G. and atorvastatin, the volume of distribution and total clearance is better than atorvastatin, does not inhibit CYP50, is not mutagenic, carcinogenic, and not hepatotoxic, has lower Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) values compared to atorvastatin. Methyl ricinoleate can potentially be an anti-inflammatory drug through the inhibition of Ang-2.

Others Information

Number of Figures: 4

Number of Tables: 4

Number of Words: 4652

Name of other Authors

1. Irham Taufiqurrahman
2. Isyana Erlita
3. Mira Hadistina
4. Juliyatin Putri Utami
5. Andi Zulkifli
6. Veni Hadju
7. Eko Suhartono
8. Muhammad Irpan Hendrawan

Name of Funders

1. ()
2. ()
3. ()

Keyword(s)

Angiotensin-2

Anti-inflammatory

Ramanian

Uploaded Document / File



An In Silico Study Anti-Inflammatory of Active Compound of Ramania Leaves Extract (*Bouea macrophylla* Griffith) Against Angiopoietin-2

Irham Taufiqurrahman^{1*}, Isyana Erlita², Mira Hadistina³, Juliyatin Putri Utami⁴, Andi Zulkifli⁵, Veni Hadju⁵, Eko Suhartono⁶, Muhammad Irpan Hendrawan⁷

Departement of Oral and Maxillofacial Surgery, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia¹

Department of Conservative Dentistry, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia²

Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin – Indonesia³

Department of Biomedicine Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia⁴

Faculty of Public Health, Hasanuddin University, Makassar – Indonesia⁵

Department of Medical Chemistry/Biochemistry, Faculty of Medicine, Lambung Mangkurat University, Indonesia⁶

Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia⁷

Corresponding Author: 1*



Keywords:

Angiopoietin-2, Anti-inflammatory, Ramania.

ABSTRACT

Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti and colleagues, the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59%. To determine the active compound binding of *Bouea macrophylla* G. (ramania) as an anti-inflammatory by inhibiting the protein angiopoietin-2 (Ang-2) in silico. Experimental design through in silico method. Methyl ricinoleate compound has RMSD (Root Mean Square Deviation) value of 0 and negative binding affinity value, hydrogen bonding, and the same residue as the comparison ligand, atorvastatin. All active compounds of *Bouea macrophylla* G. has passed the drug likeness test with Lipinski's Rule parameters. Based on the results of the ADMET test, it is known that the absorption of methyl ricinoleate compounds can be absorbed well, the absorption of Caco-2 cells is the highest compared to the 9 active compounds of *Bouea macrophylla* G. and atorvastatin, the volume of distribution and total clearance is better than atorvastatin, does not inhibit CYP50, is not mutagenic, carcinogenic, and not hepatotoxic, has lower Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) values compared to atorvastatin. Methyl ricinoleate can potentially be an anti-inflammatory drug through the inhibition of Ang-2.



This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License.

1. Introduction

Traumatic Dental Injury (TDI) is a trauma that occurs when the hard and soft tissues of the oral cavity receive an impact [1]. The prevalence of traumatic dental injury (TDI) experienced at all ages touched the percentage of 20%. According to Petti et al (2018), the prevalence of TDI in primary teeth is higher than in permanent teeth. The prevalence of TDI worldwide by bibliometric analysis in 1999-2018 touched the percentage of 6%-59% [2], [3]. TDI trauma that occurs often involves many tissues and takes a lot of time to treat, so treatment is relatively expensive and difficult. Some drugs such as antibiotics are also used in addition to surgery [1], [4].

The use of drugs in wound healing is available with various kinds and types, including the use of herbal medicines. Herbal medicine is an alternative in medicine because the price is cheap, the ingredients are relatively easy to obtain and do not cause side effects. *Bouea macrophylla* G. can be selected as a plant that can play a role in accelerating wound healing. It is known that the leaves of *Bouea macrophylla* G. contain compounds of caryophyllene, humulene; hexadecanoic acid, ethyl ester (palmitic acid); phytol; squalene; vitamin E; retinol, acetate; and γ -himachalene which has potential as an anti-inflammatory [5- 7].

Treatment of wound healing in soft tissue aims to clean the wound area from foreign objects, dead cells and bacteria so as to support the healing process. As the body's response to wound healing, there is an inflammatory process that involves: a number of endothelial growth factors. One of the proteins derived from endothelial growth factor is the protein angiopoietin-2 (Ang-2). Ang-2 is the second member of the angiopoietin family that plays a role in blood formation and is known as a protein ligand and is secreted from the receptor tyrosine kinase (Tie2). Ang-2 acts as a vascular disruptor which is its role as a natural Tie2 antagonist by counteracting the vascular-stabilizing activity of the Tie2 receptor while simultaneously blocking its interaction with its canonical agonist ligand, Ang-1 during inflammation. Thus, when the Ang-2/Tie2 signaling pathway is inhibited, vessel-in-vessel growth can be markedly enhanced in inflammation and new fields can be discovered for therapeutic exploration [6], [8- 10].

The comparison ligand used was an Ang-2 inhibitor, namely atorvastatin. The comparison protein used in protein-to-protein docking is Tyrosine Kinase-2 (Tie2). This study predicts the therapeutic target for Ang-2 by using 10 active compounds *Bouea macrophylla* G.

2. Materials & method

2.1 Ligand and Protein Preparation

Receptors namely Ang-2 and Tie2 were prepared using Biovia Discovery Studio version 21 application to remove water molecules and residues. The ligands, namely the active compound *Bouea macrophylla* G. and atorvastatin, were prepared using the Open Babel program from PyRx version 0.8 to minimize energy, optimize, and convert the format to .pdb.

2.2 Validation

The validation process was carried out by re-docking the Ang-2 protein with its natural ligand (calcium ion) (CID:336285734). The parameter used is the RMSD (Root Mean Square Deviation) value. The validation results obtained are 0. RMSD is a value associated with the deviation of the binding position. The docking

method is said to be valid if the RMSD value is 2, so the docking method can be used for the docking test of active compounds.

2.3 Protein-Ligand Docking and Visualization

Molecular docking simulation using AutoDock Vina program which is integrated with PyRx version 0.8. The analysis and visual prediction of the protein-ligand complex virtual from the docking stage were analyzed and visualized using the Biovia Discovery Studio version 21 application. The interaction side was analyzed based on the residual ligand interaction and structural conformation. Ang-2 was also docked with atorvastatin to compare the binding affinity values of 10 *Bouea macrophylla* G compounds.

2.4 Prediction of drug-likeness, pharmacokinetics, and safety

Lipinski's Rule of 5 used to predict drug similarity to the active compound, which was evaluated by the pkCSM website (<http://biosig.unimelb.edu.au/pkcsm/prediction>) and PubChem (<https://pubchem.ncbi.nlm.nih.gov/>).

3. Results

In Table 1. it can be seen that the highest molecular weight is owned by atorvastatin with a weight of 558.65 g/mol and the lowest weight is a compound of humulene and a compound of γ -himachalene with a weight of 204.357 g/mol. The best logP values were owned by *carophyllene* compounds and γ -himachalene compounds with a logP of 4.7252. While the largest is squalene compound with logP 10,605. All of the active compounds have good hydrogen acceptors, *Bouea macrophylla* G. Meanwhile, all of the tested active compounds of *Bouea macrophylla* G. have < 5. The widest topological polar surface area (TPSA) (Table 1) is owned by atorvastatin compounds with an area of 112. Based on Table 1. it was found that all active compounds of *Bouea macrophylla* G. leaf extract passed the Lipinski's rules test.

All the active compounds of *Bouea macrophylla* G. tested (Table 2.) were well absorbed in the human intestine. The highest absorption of Caco-2 cells was methyl ricinoleate with a value of 1.57 log cm/s. The highest VD_{ss} value was found in vitamin E compounds with a VD_{ss} value of 0.873 log L/kg.

The 10 active compounds tested *Bouea macrophylla* G. (Table 2.) did not act as CYP2D6 inhibitors, so their pharmacokinetic properties were enzymatic. The highest total clearance value was owned by *squalane* compound with a value of 1.791 log mL/minute/kg.

All tested *Bouea macrophylla* G. compounds were neither mutagenic nor carcinogenic, nor was atorvastatin. In the hepatotoxicity test (Table 2.), it was found that all *Bouea macrophylla* G. compounds were not hepatotoxic, except for the retinol compound, acetate, which resulted in hepatotoxicity as well as *atorvastatin*. The highest LD₅₀ is owned by atorvastatin with a value of 2.877 mol/kg. The highest LOAEL was owned by *atorvastatin* with a value of 4.839 mol/kg.

Table 3. The binding affinity value obtained varies from -3.3 kcal/mol to -6.5 kcal/mol. The lowest bond value was owned by the Ang-2_atorvastatin bond of -6.5 kcal/mol. While the highest is the Ang2-palmitic acid bond. Ang-2_Bond Methyl ricinoleate has 2 hydrogen bonds. In addition, the Ang-2_methyl ricinoleate bond has the same residue as the Ang-2_atorvastatin bond residue, namely the GLU35 residue. The result of Ang-2_pristanal docking also has 2 hydrogen bond interactions. Meanwhile, Ang-2_retinol, acetate; Ang-2_phytol; and Ang-2_palmitic acid has a hydrogen bond type interaction, while the Ang-2_γ-himachlene bond; Ang-2_vitamin E bond; bond Ang-2_carophyllene; bond Ang-2_humulene; Ang-2_squalene bonds have no hydrogen-type bond interactions.

The most negative binding affinity value from the results of docking to protein (Table 4.) is the result of docking tyrosine kinase-2 (Tie2) with Ang-2_ *carophyllene* bonds with a value of -8.1 kcal/mol, higher than the binding affinity value of Tie2_Ang- 2_ *atorvastatin* with a value of -7.5 kcal/mol. While the highest is Tie2_Ang-2_ *palmitic acid* with a value of -4 kcal/mol.

The amino residues on the interaction bonds found in the protein-to-protein docking results (Table 4.) were almost all similar to the amino acid residues from the docking of Ang-2 with the active compounds *Bouea macrophylla* G. and *atorvastatin*, except for the docking results of Tie2_Ang-2_ *pristanal* at residues MET857 and PHE869, Tie2_Ang-2_ *methyl ricinoleate*. Tie2_Ang-2_ *methyl ricinoleate* has the same residues with a total of 12 residues that are the same as Tie2_Ang-2_ *atorvastatin*, namely at residues LYS855, ARG856, VAL829, LEU839.

Hydrogen bond interactions from protein to protein docking results (Table 4.) from Tie2_Ang-2_10 active compound *Bouea macrophylla* G. and Tie2_Ang-2_ *atorvastatin* bonds were mostly found in Tie2_Ang-2_ *atorvastatin* bonds with 5 hydrogen bonds at residues LYS855, ARG856, LYS858 and bonds Tie2_Ang-2_ *methyl ricinoleate* on residues LYS855, ARG856 (3.25349 and 3, 37493), GLN837, and CO. Meanwhile, the Tie2_Ang-2_ *carophyllene* bond, the Tie2_Ang-2_ *pristanal* bond, the Tie2_Ang-2_ *humulene* bond, and the Tie2_Ang-2_ *γ-himachlane* bond did not have hydrogen bonds.

Table 1. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand *Atorvastatin* Correlation with Lipinski's Rule.

Compound	Molecular Weight (g/mol)	LogP	Hydrogen Acceptors (n)	Hydrogen Donor (n)	TPSA (Topological Polar Surface Area)	Lipinski's Law Deviations	Pass/No
<i>Carophyllene</i>	204.537	4.7252	0	0	0	0	Graduated
<i>2-Methyl-cis-7, 8-epoxynonadecane (Pristanal)</i>	296.539	6.8911	1	0	12.5	1	Graduated
<i>Humulene</i>	204,357	5.0354	0	0	0	1	Graduated
<i>Hexadecanoic acid, ethyl ester (Palmitic acid)</i>	284,484	6.1884	1	1	37.3	1	Graduated
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans- (Methyl ricinoleate)</i>	312,494	5.5673	2	1	46.5	1	Graduated
<i>Phytol</i>	296.539	6.3641	1	1	20.2	1	Graduated

<i>Retinol, Acetate</i>	328,496	6.0811	2	0	26.3	1	Graduated
Vitamin E	430.717	8.84026	2	1	29.5	1	Graduated
<i>γ-himachalene</i>	204,357	4.7252	0	0	0	0	Graduated
<i>Squalene</i>	410.73	10,605	0	0	0	1	Graduated
<i>Atorvastatin</i>	558.65	6,3136	5	4	112	2	Graduated

Table 2. Results of Physicochemical Properties and Toxicity of Active Compounds *Bouea macrophylla* G. and Comparative Ligand Atorvastatin

Compound	Caco-2 permeability (nm. sec-1)	Human Intestinal Absorption (%)	VDss (log L/kg)	CYP 2D6 Inhibitor	Total Clearance	AMES Toxicity	Hepatotoxicity	Oral Rate Acute Toxicity (LD50) (mol/kg)	Oral Rate Chronic Toxicity (LOAEL) (log mg/kg_bw/day)
<i>Carophyllene</i>	1.434	95.304	0.653	No	1.088	No	No	1,678	1.44
<i>2-Methyl-cis-7, 8-epoxy-nonadecane</i>	1.32	91,567	0.451	No	1,631	No	No	1.382	1.028
<i>Humulene</i>	1.421	94,682	0.505	No	1,282	No	No	1,766	1.336
<i>Hexadecanoic acid, ethyl ester</i>	1.38	92,158	0.679	No	1,678	No	No	1.46	3.298
<i>Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-</i>	1.57	91,956	0.509	No	1.615	No	No	1.573	2,701
<i>Phytol</i>	1.487	89,892	0.416	No	1,686	No	No	1,646	1.024
<i>Retinol, Acetate</i>	1.188	94.33	0.408	No	1.503	No	Yes	1,673	2.276
Vitamin E	1,215	90,045	0.873	No	0.801	No	No	2,243	2.445
<i>γ-himachalene</i>	1.418	94.556	0.648	No	1.093	No	No	1,681	1.346
<i>Squalene</i>	1.193	89,581	0.282	No	1,791	No	No	1995	0.902

<i>Atorvastatin</i>	0.23	59,861	$\frac{-1.91}{8}$	No	$\frac{0.43}{7}$	No	Yes	2.877	4.839
---------------------	------	--------	-------------------	----	------------------	----	-----	-------	-------

Table 3. Results of Docking Ang-2 with *Bouea macrophylla* G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-5.3	ILE309, LYS310	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxy-nonadecane</i> (Pristanal)	-4.2	GLY347, GLY345 LYS310, VAL344, ILE309, PRO349, LYS340	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Humulene</i>	-4.8	-	-
<i>Hexadecanoic acid, ethyl ester</i> (Palmitic acid)	-3.3	PHE346 ILE309, VAL344, LYS310	<i>hydrogen</i> <i>Hydrophobic</i>
*Oxiraneundecanoic acid, 3-pentyl-methyl ester, trans-(Methyl ricinoleate)	-4.5	GLU395, *GLU358 PRO303	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Phytol</i>	-4	GLU308 LYS310 PRO349, ILE309, VAL344	<i>hydrogen</i> <i>Unfavorable</i> <i>Hydrophobic</i>
<i>Retinol, Acetate</i>	-5.7	LYS372 ALA494, VAL370, LEU386	<i>hydrogen</i> <i>Hydrophobic</i>
Vitamin E	-5.4	PHE469, PRO452, PHE469, PHE469, TYR475, TYR475	<i>Hydrophobic</i>
<i>γ-himachalene</i>	-5.8	MET458	<i>Hydrophobic</i>
<i>Squalene</i>	-4.4	ILE309, LYS310, PRO349, VAL344 VAL344	<i>Hydrophobic</i>
<i>Atorvastatin</i>	-6.5	SER393, TYR391 *GLU358, *GLU358 ASN365, HIS402	<i>hydrogen</i> <i>Halogen</i> <i>Unfavorable</i>

* =The same residue as the comparison ligand




Figure 1.a. 3D Structure of Ang-2 docked with Oxiraneundecanoic acid, 3-penthyl-methyl ester, trans-(methyl ricinoleate), b. 2D structure of Ang-2 docked with Oxiraneundecanoic acid, 3-penthyl-methyl ester, trans-(methyl ricinoleate)




Figure 2.a. 3D structure of Ang-2 docked with Atorvastatin, b. 2D structure of Ang-2 docked with Atorvastatin

Table 4. Results of Docking Tie2_Ang-2 with Bouea macrophylla G. Active Compound and Comparative Ligand Atorvastatin

Compound	Binding Affinity (kcal/mol)	Amino Residue	Category
<i>Carophyllene</i>	-8.1	*VAL829	<i>Hydrophobic</i>
<i>2-Methyl-cis-7, 8-epoxynonadecane (Pristanal)</i>	-4.7	*VAL829, *VAL829, *VAL829, *ARG856, *ARG856, *LYS858, *LYS858, MET857, *LEU839, *LEU839, *ARG856, *VAL829, PHE869	<i>Hydrophobic</i>
<i>Humulene</i>	-7.9	VAL829	<i>Hydrophobic</i>
<i>Hexadecanoic acid, ethyl ester (palmitic acid)</i>	-4	*LYS855, *ARG856 *VAL829, *VAL829, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Oxiraneundecanoic acid, 3-penthyl-methyl ester, trans-(Methyl ricinoleate)</i>	-5.6	*LYS855, *ARG856, GLN837, *ARG856, CO, *VAL829, *VAL829, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *LEU839	<i>hydrogen</i> <i>Hydrophobic</i>
<i>Phytol</i>	-5	*ARG856	<i>hydrogen</i>

		*VAL829, *VAL829, *LEU839, *LYS858, *LYS858	<i>Hydrophobic</i>
<i>Retinol, Acetate</i>	-6.7	THR1016, ASN1018 TYR1012, TYR992, VAL1014, TYR1012	<i>hydrogen Hydrophobic</i>
Vitamin E	-6.8	*LYS855	<i>Hydrogen Bond; Electrostatic</i>
<i>γ-himachalene</i>	-7.1	*VAL829, *VAL829, *LEU839, *ARG856, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrophobic</i>
<i>Squalene</i>	-4.8	LYS1059, LEU1061, ALA1114, LYS1059, TYR1068, TYR1068	<i>Hydrophobic</i>
<i>Atorvastatin</i>	-7.5	*LYS855, *ARG856, *LYS858, *ARG856	<i>Hydrogen Bond</i>
		*LYS855	<i>Hydrogen Bond; Electrostatic</i>
		*LEU839, *ARG856, *VAL829, *VAL829, *LEU839, *ARG856	<i>Hydrophobic</i>




Figure 3.a. Result 3D Structure Docking Protein Tie2_Ang-2 with *Methyl Ricinoleate*, b. 2D Structure of Tie2_Ang-2 Protein Docking Result with *Methyl Ricinoleate*




Figure 4. a. Result 3D Structure of Docking Protein Tie2_Ang-2 with Atorvastatin, b. 2D Structure of Tie2_Ang-2 Protein Docking Results with Atorvastatin

4. Discussion

Table 1. All active compounds of *Bouea macrophylla* G. can be potential candidates for oral drugs because all active compounds of *Bouea macrophylla* G. leaves passed the Lipinski test. [11] stated that good absorption is absorption that meets 3 or more Lipinski's rules which include: molecular weight not more than 500 g/mol, number of H-bond acceptors not more than 10, Number of H-bond donors not more than 5, and LogP not more than 5 (or MlogP > 5) [12].

In the pharmacokinetic test results (Table 2.), all tested active compounds of *Bouea macrophylla* G. were well absorbed in the human intestine, because the percentage absorption of all tested compounds was >89%. Based on [13], the value of good absorption in the human intestine is 70-100% [14].

Caco-2 cells are permeability parameters used to determine drug transport through specialized epithelium derived from human colonic adenocarcinoma which has multiple transport pathways. The parameter categories of Caco-2 cells were >70 nm/sec (high compound permeability); 4-70 nm/sec (medium permeability); <4 nm/sec (low compound permeability) [14], [15]. In Table 2. it can be seen the absorption of the compound active *methyl ricinoleate* has a value of 1.57 log cm/s which is low permeability. Volume of distribution (VDss) is the ability to interact between the distribution phase and the second phase of pharmacokinetics [13]. A compound can be evenly distributed with the same concentration in blood plasma if the volume of distribution is > 0.45 log L/kg, so it can be seen if the compound *methyl ricinoleate* < 0.45 log L/kg, meaning that it is not evenly distributed in blood plasma [15]. Total clearance is the total elimination of a drug concentration, which is at this clearance the concentration of a drug becomes exhausted or does not exist in the body [13]. It can be seen in Table 2. The amount of absorption of the active compound *Bouea macrophylla* G. tested and released was equally large so that the ADME process that took place was balanced.

The 10 active compounds tested *Bouea macrophylla* G. (Table 2.) did not act as CYP2D6 inhibitors. Cytochrome P450 is an enzyme that is responsible for the metabolism of a drug. Cytochrome P450 has two main isoforms, namely CYP2D6 and CYP3A4 [15]. So if a CYP2D6 inhibitor is found in a compound, it is feared that it will change a drug's pharmacokinetics.

AMES test is a simple way to test the properties of compounds in the form of mutagenic and carcinogenic properties as mutagenic frames [13], [16]. In this study (Table 2.) it was found that all tested *Bouea*

macrophylla G. compounds were neither mutagenic nor carcinogenic, as was atorvastatin. The safety test of all tested Bouea macrophylla G. active compounds was made by determining the acute and chronic lethal doses as Oral Rate Acute Toxicity (LD50) and Oral Rate Chronic Toxicity (LOAEL) (Table 2), respectively. The LD50 of *methyl ricinoleate* compound is 1,573 mol/kg where the LD50 dose of *methyl ricinoleate* compound is smaller than the LD50 of atorvastatin with a value of 2,877 mol/kg. Meanwhile, the LOAEL value of *methyl ricinoleate* is 2,701 log/mg/kg_bw/day, which means it is lower than the LOAEL for atorvastatin with a value of 4.839 log/mg/kg_bw/day [13].

Table 4. shows that the results of docking angiopoietin-2 (Ang-2) with 10 tested active compounds Bouea macrophylla G. and with atorvastatin resulted in binding affinity varying from -3.3 kcal/mol to -6.5kcal/mol. The binding affinity value has the potential to predict the strength of the interaction between the ligand and the receptor, the more negative or the smaller the affinity value, the more stable and strong the bond is. So it can be seen that the 10 active compounds tested Bouea macrophylla G. have less stable bonds than *atorvastatin* [13], [17].

Hydrogen bonding provides a stronger affinity and plays an important role in stabilizing the structure, so it is very important in the development of drug design. The closer the distance formed in a bond, the stronger the bond and the more significant the activity [13], [18], [19]. Existence of the same residue is very important for the resulting pharmacological effect because the same residue with the reference ligand (comparison drug) is predicted to show activity at the receptor. An active compound is predicted to have a strong bond with the target protein if it is able to bind strongly with hydrogen bonds with the same amino acid residue compared to the control compound (*atorvastatin*) [20], [21].

Table 4. shows that Tie2 can interact with the Ang-2_ bond of the active leaf compound Bouea macrophylla G. and the Ang-2_ *atorvastatin* bond. The presence of protein-to-protein docking interactions is indicated by the amino acid bonds between the ligand and the receptor in the form of hydrogen, hydrophobic, and electrostatic bonds. The type of bond determines the strength of the binding between the drug and the receptor. Bioactive compounds are predicted to have a strong bond with the target receptor if they are able to bind tightly through hydrogen bonds and bind to one amino acid residue from the active site compared to comparison or inhibitor compounds [22]. The result of docking between Tie2_Ang-2_Vitamin E bonds (Table 4.) resulted in the type of interaction in the form of electrostatic hydrogen. Electrostatic interactions serve to increase the stability of the ligand to the receptor [23].

The binding affinity value of Tie2_Ang-2_ *methyl ricinoleate* bond was more negative than that of Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *atorvastatin* (Table 4.). Although the Ang-2_ *methyl ricinoleate* bond has a weaker binding affinity than the Ang-2_ *atorvastatin* bond, the Ang-2_ *methyl ricinoleate* bond has the same residue as Ang-2_ *atorvastatin* and has one hydrogen bond. Likewise, Tie2_Ang-2_ *methyl ricinoleate* which has the same residues with Tie2_Ang-2_ *atorvastatin* bonds between the results of protein to protein docking with Ang-2 bonds and 10 active compounds Bouea macrophylla G. and has the most hydrogen bonds between protein to protein docking with bonds Ang-2 and 10 active compounds Bouea macrophylla G. and *atorvastatin*. So that it can be seen if the active compound *methyl ricinoleate* has the most stable and best bond compared to the Ang-2_9 bond of the other active compound Bouea macrophylla G. tested. This is in line with the research of [13] that a good compound is a compound with a negative binding affinity, has a hydrogen bond, and has the same residue with the protein-ligand bond of comparison. In addition, it is necessary to know if hydrophobic bonds which are non-covalent type bond interactions also play an important role in stabilizing proteins, and increasing the inhibitor's affinity for enzymes [24].

The existence of hydrogen bonds is very important in a drug development. The hydrogen bonds shared by Ang-2_ *methyl ricinoleate* and Tie2_Ang-2_ *methyl ricinoleate* play a key role in molecular recognition, structural stability, enzyme catalysis, drug partitioning and permeability [25]. Thus, *methyl ricinoleate* compounds are able to inactivate Ang-2 to block Ang-2/Tie2 signaling as a trigger for inflammation in pathological conditions. The increased expression of Ang-2 under pathological conditions will promote inflammation [26], [27]. During inflammation, Ang-2 is rapidly secreted from the Weibel-Palade body on EC (endothelial cells) and counteracts the vascular stabilizing activity of the Tie2 receptor by blocking its interaction with its canonical agonist ligand, Ang-1. Ang-2 released by exocytosis of WPB (Weibel Palade Body) interferes with the recruitment of pericytes to new blood vessels during angiogenesis by blocking Ang-1/Tie2 autocrine signaling [28- 30]. By inhibiting the Ang-2/Tie2 signaling pathway, vessel-in-vessel growth can be clearly promoted in inflammation. Pericyte coverage which increases after Ang-2 is inhibited will affect the stabilization of new blood vessels. VE-Cad accumulation will decrease and phosphorylation will increase. Therefore, by inhibiting Ang-2, the maturation of blood vessels will increase [31]. In addition, the development of a drug needs to pay attention to good pharmacokinetics, the right balance between hydrophilicity and lipophilicity [25]. One indicator that can be used is Lipinski's Rule of Five. *Methyl ricinoleate* can inhibit pro-inflammatory agents such as carrageenan. Thus, the *methyl ricinoleate* compound is able to inactivate Ang-2 to form the process of blocking the Ang-2/Tie2 signal as a trigger for inflammation in pathological conditions. The effect is as an inhibitor of vasodilation, protein extravasation and edema. Thus, based on the results of the study (Table 1.), the *methyl ricinoleate* compound has been declared to have passed and fulfilled the pharmacokinetic requirements.

5. Conclusion

Based on the results of research that has been carried out, the active compound methyl ricinoleate from *Bouea macrophylla* G. can potentially be a candidate for anti-inflammatory drugs through inhibition of Ang-2.

6. References

- [1] L. Ram, "Epidemiology and outcomes of traumatic dental injuries: A review of the literature," *Aust Dent J*, vol. 61, 2016.
- [2] A. Antipovienė, J. Narbutaitė, and J. Virtanen, "Traumatic Dental Injuries, Treatment and Complications in Children and Adolescents: A Register-Based Study," *euro. J. Dent.*, 2021.
- [3] F. Liu, T. Wu T, and G. Lei, "Worldwide tendency and perspectives in traumatic dental injuries: A bibliometric analysis over two decades (1999-2018)," *Dent Traumatol*, vol. 36, no. 5, 2020.
- [4] A. DiAngelis, J. Andreasen, and K. Ebeleseder, "International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 1. Fractures and luxations of permanent teeth," *Dent Traumatol*, vol. 28, no. 1, 2012.
- [5] Taufiqurrahman I, Dina H. Test of Ethanol Solvent Concentration Variation on Total Flavonoid Level of *Ramania* (*Bouea Macrophylla* Griffith) Leaf Extract. 2016;000(12):2.
- [6] Rosita JM, Taufiqurrahman I, Edyson. Differences in Total Flavonoids between Maceration and Soxhletation Methods on *Ramania* (*Bouea macrophylla* Griff) Leaf Extract. *Dentino J Dentist*. 2017;1(1):22–7.

- [7] NH Nguyen, TT Nguyen, PC Ma, QTH Ta, TH Duong, and VG Vo, "Potential antimicrobial and anticancer activities of an ethanol extract from bouea macrophylla," *Molecules*, vol. 25, no. 8, 2020, doi:10.3390/molecules25081996.
- [8] ZX Yan, Y. Luo, and NF Liu, "Blockade of angiotensin-2/Tie2 signaling pathway specifically promotes inflammation-induced angiogenesis in m(Ram, Rammouse cornea)," *int. J. Ophthalmol.*, vol. 10, no. 8, pp. 1187–1194, 2017, doi:10.18240/ijo.2017.08.01.
- [9] AC Mirando, RL E Silva, Z. Chu, PA Campochiaro, NB Pandey, and AS Popel, "Suppression of ocular vascular inflammation through peptide-mediated activation of angiotensin-tie2 signaling," *int. J. Mol. science.*, vol. 21, no. 14, pp. 1–20, 2020, doi:10.3390/ijms21145142.
- [10] M. Teichert et al., "Pericyte-expressed Tie2 controls angiogenesis and vessel maturation," *Nat. Commun.*, vol. 8, no. May, pp. 1–12, 2017, doi:10.1038/ncomms16106.
- [11] H. Bond and S. Neidle, "Lipinski's Rule of Five Design Principles for Quadruplex-binding Small Molecules," 2019.
- [12] SK Enmozhi, K. Raja, I. Sebastine, and J. Joseph, "Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach," *J. Biomol. Struct. Dyn.*, vol. 0, no. 0, pp. 1–7, 2020, doi:10.1080/07391102.2020.1760136.
- [13] Utami JP, Kurnianingsih N, Faisal MR. An in Silico Study of the Cathepsin L Inhibitory Activity of Bioactive Compounds in *Stachytarpheta jamaicensis* as a Covid-19 Drug Therapy. *Makara J Sci.* 2022;26(1).
- [14] J. Olaleye, O. Moses, and O. Titilope, "Covid-19 treatment: Investigation on the phytochemical constituents of *Vernonia amygdalina* as potential Coronavirus-2 inhibitors," *Comput. Toxicol.*, no. January, 2021.
- [15] A. Kirtishanti, Siswandono, S. Hardjono, and D. Kesuma, "Molecular Docking of Benzoylurea Derivatives as Potential Anti-Breast Cancer Agent and Its Admet Profiles," *J. Glob. Pharma Technol.*, vol. 12, no. 6, pp. 726–735, 2020.
- [16] KH Hsu, BH Su, YS Tu, OA Lin, and YJ Tseng, "Mutagenicity in a molecule: Identification of core structural features of mutagenicity using a scaffold analysis," *PLoS One*, vol. 11, no. 2, p. 2, 2016, doi:10.1371/journal.pone.0148900.
- [17] N. Nursamsiar, MM Mangade, A. Awaluddin, S. Nur, and A. Asnawi, "In Silico Study of Aglycon Curculigoside A and Its Derivatives as -Amylase Inhibitors," *Indonesia. J. Pharm. science. Technol.*, vol. 7, no. 1, p. 29, 2020, doi:10.24198/ijpst.v7i1.23062.
- [18] Y. Bare, AD Kuki, SSN Daeng Tiring, AH Rophi, GC Krisnamurti, and DR Tirto Sari, "In Silico Study: Prediction of the Potential of Caffeic Acid As ACE inhibitor," *El-Hayah*, vol. 7, no. 3, pp. 94–98, 2020, doi:10.18860/elha.v7i3.10053.
- [19] R. Mutiah, AF Firdausy, YYA Indrawijaya, and H. Hibbatullah, "In Silico Prediction of

Heliannuol A, B, C, D, and E Compounds on Estrogen Receptor Agonists,"Indonesia. J. Cancer Chemoprevention, vol. 12, no. 1, p. 37, 2021, doi:10.14499/indonesianjcanchemprev12iss1pp37-45.

[20] Barelier, T. Sterling, MJ O'Meara, and BK Shoichet, "The Recognition of Identical Ligands by Unrelated Proteins,"ACS Chem Biol, vol. 176, no. 3, pp. 139–148, 2016, doi:10.1021/acscchembio.5b00683.The.

[21] Ruswanto R, Mardianingrum R, Lestari T, Nofianti T, Tuslinah L, Nurmalik D. In silico study of the active compounds in bitter melon (*Momordica charantia* L) as antidiabetic medication. Pharmacy. 2018;8(2):194.

[22] DS Damayanti, DH Utomo, and C. Kusuma, "Revealing the potency of *Annona muricata* leaves extract as FOXO1 inhibitor for diabetes mellitus treatment through computational study,"Silicon Pharmacol., vol. 5, no. 1, 2017, doi:10.1007/s40203-017-0023-3.

[23] MJ Yunta, "Docking and Ligand Binding Affinity: Uses and Pitfalls María,"Am. J. Models. Optimistic., vol. 4, no. January 2016, pp. 74–114, 2016, doi:10.12691/ajmo-4-3-2.

[24] Ramayanti K, Riza H, Fajriaty I. Molecular Docking of Drymaritin, Triptonine a and Triptonine b Compounds Against HIV Enzymes. J Mhs Farm Fak Kedokt UNTAN. 2019.

[25] T. Coimbra, R. Feghali, R. Ribeiro, M. Ramons, and P. Fernandes, "The Importance of Intramolecular Hydrogen Bonds on The Translocation of The Small Drug Piracetam Through a Lipid Bilayer,"R. Soc. Chem., vol. 11, no. 2, p. 89, 2021.

[26] C. Dalyet al., "Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition," Cancer Res., vol. 73, no. 1, pp. 108–118, 2013, doi:10.1158/0008-5472.CAN-12-2064.

[27] T. Shlamkovich, L. Aharon, WA Barton, and N. Papo, "Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoietin-2 ligands as candidates for antiangiogenesis therapy,"Oncotarget, vol. 8, no. 20, pp. 33571–33585, 2017, doi:10.18632/oncotarget.16827.

[28] SM Parikh, "The Angiopoietins and Tie2 in Vascular Inflammation,"HHS Public Access, vol. 24, no. 5, 2017.

[29] M. Cossuttaet al., "Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis," Arterioscler. Thromb. Vasc. Biol., vol. 39, no. 9, pp. 1843–1858, 2019, doi:10.1161/ATVBAHA.119.313021.

[30] M. Jeltsch and V. Leppa, "Tyrosine Kinase-Mediated Receptors," pp. 1–22, 2016.

[31] F. Baganhaet al., "Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization," Angiogenesis, vol. 24, no.3, pp. 567–581, 2021, doi:10.1007/s10456-021-09767-9.



Azerbaijan Medical Journal

Dear Dr. Irham Taufiqurrahman,











Our azerbaijan medical journal website has been attacked by some Australian hackers. Your papers and data are totally safe.

our new website is: www.azerbaijanmedicaljournal.net

Thank you,
Admin Board
Azerbaijan Medical Journal

N.B: For Any Queries, Please mail to support@azerbaijanmedicaljournal.net
and related documents mail to admin@azerbaijanmedicaljournal.net

resume.io



Azerbaijan Medical Journal ← Show this widget in your own website

Q4 Medicine (miscellaneous) best quartile

SJR 2022 0.19

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```

SCImago Graphica

Explore, visually communicate and make sense of data with our new data visualization tool.



Source details

Feedback >

Azerbaijan Medical Journal

Scopus coverage years: from 1961 to 1963, from 2002 to 2013, from 2016 to Present

Publisher: Izdate!stvo Elm

ISSN: 0005-2523

Subject area: Medicine: General Medicine

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[Source Homepage](#)

CiteScore 2022

0.5



SJR 2022

0.194



SNIP 2022

0.222



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)



Improved CiteScore methodology

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022

$$0.5 = \frac{162 \text{ Citations 2019 - 2022}}{350 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$0.5 = \frac{136 \text{ Citations to date}}{262 \text{ Documents to date}}$$

Last updated on 07 June, 2023 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Medicine		
General Medicine	#662/830	20th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site >](#)

About Scopus

- [What is Scopus](#)
- [Content coverage](#)
- [Scopus blog](#)
- [Scopus API](#)
- [Privacy matters](#)

Language

- [日本語版を表示する](#)
- [查看简体中文版本](#)
- [查看繁體中文版本](#)
- [Просмотр версии на русском языке](#)

Customer Service

- [Help](#)
- [Tutorials](#)
- [Contact us](#)

